Cape Town Smile Studios

References 501 to 1128 PDF Print E-mail






The Big Dental Lie (1st Ed.) by Dr IR Visser

Reference list 501 - 1128


501 Miura K, et al. Establishment and characterization of methyl mercuryresistant PC12 cell line. Environ Health

Perspect, 1994;102( 3):313–5.
502 Rice D. Evidence of delayed neurotoxicity produced by methyl mercury. Neurotoxicology, 1996;17:583–96.
503 Weiss B, et al. Silent latency periods in methyl mercury poisoning and in neurodegenerative disease.

Environ Health Perspec, 2002;110(5):851-4
503 Martyn CN, et al. Motoneuron disease and past poliomyelitis in England and Wales. Lancet , 1988 Jun

11;1(8598):1319-22.
505 Evans HL, et al. Methyl mercury: exposure duration and regional distribution as determinants of neurotoxicity

in nonhuman primates. Toxicol Appl Pharmacol, 1977;41:15–33.
506 Weiss B, Simon W. Quantitative perspectives on the long term toxicity of methyl mercury and similar poisons.

In: Behavioral Toxicology (Weiss B, Laties VG, eds). New York:Plenum Press, 1975;429–438.
507 Bahiga LM, et al. Neurological syndromes produced by some toxic metals encountered industrially or

environmentally. Z Ernahrungswiss, 1978 Jun;17(2):84-8.
508 Magos L. Mercury-blood interaction and mercury uptake by the brain after vapour exposure. Environ Res,

1967 Dec;1(4):323-37.
509 Magos L, et al. Uptake of Mercury by the Brain. Brit J Ind Med, 1968;25:315-8.
510 Berlin M, et al. Uptake and retention of mercury in the mouse brain. A comparison of exposure to mercury

vapour and intravenous injection of mercuric salt. Arch Environ Health, 1966:12;33-42.
511 Magos L, et al. Uptake of Mercury by the Brain. Brit J Ind Med, 1968:25:315-8.
512 Eggleston DW, et al. Correlation of dental amalgam with mercury in brain tissue. J Prosth Dent,

1987;58(6):704-7.
513 Friberg L, et al. Mercury in the central nervous system in relation to amalgam fillings. Swed Med J,

1986;83(7):519-22.
514 Nylander M, et al. Mercury in pituitary glands of dentists. Lancet, 1986;22:442.1.
515 Buchet JP, et al. Influence of DMPS and DMSA on the mobilization of mercury from tissues of rats

pretreated with mercuric chloride, phenylmercury acetate or mercury vapours. Toxicology,

1+B1001989 Mar:54(3):323-33.
516 Mokrzan EM, et al. Methyl mercury-thiol uptake into cultured brain capillary endothelial cells on amino acid

system L. J Pharmacol Exp Ther, 1995 Mar:272(3):1277-84.
517 Siblerud RL. The relationship between mercury from dental amalgam and mental health. Am J Psychother,

1989 Oct;43(4):575-87.
518 Siblerud RL, et al. Psychometric evidence that mercury from silver dental fillings may be an etiological factor

in depression, excessive anger and anxiety. Psychol Rep, 1994 Feb;74(1):67-80.
519 Malt UF, et al. Physical and mental problems attributed to dental amalgam fillings: a descriptive study of 99

self-referred patients compared with 272 controls. Psychosom Medicine, 1997;59:32-41.


520 Tarabová B, et al. Inorganic mercury and methylmercury inhibit the Cav3.1 channel expressed in human

embryonic kidney 293 cells by different mechanisms. J Pharmacol Exp Ther, 2006 Apr;317(1):418-27.


521 Denny MF, et al. Mercurial-induced alterations in neuronal divalent cation homeostasis. Neurotoxicology,

Spring 1996;17(1):47-61.


522 Denny MF, et al. Methyl mercury alters intra synaptosomal concentrations of endogenous polyvalent cations.

Toxicol Appl Pharmacol, 1993 Oct;122(2):222-32.


523 Denny MF, et al. Methyl mercury-induced elevations in intra synaptosomal zinc concentrations: an 19F-NMR

study. J Neurochem, 1994 Jul;63(1):383-6.


524 Limke TL, et al. Acute exposure to methyl mercury causes Ca2+ dysregulation and neuronal death in rat

cerebellar granule cells through an M3 muscarinic receptor-linked pathway. Toxicol Sci, 2004 Jul;80(1):60-8.


525 Björkman L, et al. Mercury in human brain, blood, muscle and toenails in relation to exposure: an autopsy

study. Environ Health, 2007 Oct 11;6:30.


526 Mutter J, et al. Alzheimer disease: mercury as pathogenetic factor and apolipoprotein E as a moderator.

Neuro Endocrinol Lett, 2004 Oct;25(5):331-9.


527 Ritchie K, Dupuy AM. The current status of apo E4 as a risk factor for Alzheimer's disease: an

epidemiological perspective. Int J Geriatr Psychiatry, 1999 Sep;14(9):695-700.


528 Wojcik DP, Haley BE. et al. Mercury toxicity presenting as chronic fatigue, memory impairment and

depression: diagnosis, treatment, susceptibility and outcomes in a New Zealand general practice setting

(1994-2006). Neuro Endocrinol Lett, 2006 Aug:27(4):415-23.


529 Pendergrass JC, et al. Mercury vapour inhalation inhibits binding of GTP to tubulin in rat brain: similarity to a

molecular lesion in Alzheimer diseased brain. Neurotoxicology, 1997;18(2):315-24.


530 Pendergrass JC, Haley BE. Inhibition of brain tubulin-guanosine 5'-triphosphate interactions by mercury:

similarity to observations in Alzheimer's diseased brain. Met Ions Biol Syst, 1997;34:461-78.


531 Mutter J, et al. Mercury and Alzheimer's disease. Fortschr Neurol Psychiatr, 2007 Sep;75(9):528-38.


532 Pendergrass JC, Haley BE. Inhibition of brain tubulin-guanosine 5'-triphosphate interactions by mercury:

similarity to observations in Alzheimer's diseased brain. Met Ions Biol Syst, 1997;34:461-78.


533 Pendergrass JC, Haley BE. Inhibition of brain tubulin-guanosine 5'-triphosphate interactions by mercury:

similarity to observations in Alzheimer's diseased brain. Met Ions Biol Syst, 1997;34:461-78.


534 Duhr EF, et al. HgEDTA complex inhibits GTP interactions with the E site of Brain B-Tubulin. Toxicol Appl

Pharmacol, 1993;122:273-80.


535 Haley B, et al. Use of photo affinity labeling and 2-D electrophoresis to identify changes in nucleotide binding

proteins in brain and CSF: A Potential diagnostic technique for neurological diseases. Amer Assoc

Pharmaceut Scientists, 1995.


536 Haley B, et al. Meso-2,3-dimercaptosuccinic acid (DMSA) partially restores [32P]8N3GTP-b-tubulin

interactions to both Alzheimer's Diseased (AD) brains and to HgEDTA treated control brains.

Experim Biol, 1993.


537 Pendergrass JC, Haley BE. Inhibition of brain tubulin-guanosine 5'-triphosphate interactions by mercury:

similarity to observations in Alzheimer's diseased brain. Met Ions Biol Syst, 1997;34:461-78.


538 Ehmann WD, et al. Brain trace elements in Alzheimer's disease. Neurotoxicology Spring,

1986:7(1):195-206.


539 Thompson CM, et al. Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology Spring,

1988;9(1):1-7.


540 Wenstrup D, et al. Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains.

Brain Res, 1990 Nov;12:533(1):125-31.


541 Ehmann WD, et al. Brain trace elements in Alzheimer's disease. Neurotoxicology, 1986

Spring;7(1):195-206.


542 Cornett CR, et al. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain.

Neurotoxicology, 1998 Jun;19(3):339-45.


543 Basun H, et al. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's

disease. J Neural Transm Park Dis Dement Sect, 1991;3(4):231-58.


544 Vance DE, et al. Trace element imbalances in hair and nails of Alzheimer's disease patients.

Neurotoxicology, 1988 Summer;9(2):197-208.


545 Hock C, et al. Increased blood mercury levels in patients with Alzheimer's disease. J Neural Transm, 1998:105(1):59-68.


546 Olivieri G, et al. Mercury induces cell cytotoxicity and oxidative stress and increases b-amyloid

secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochemistry,

2000;74:231.


547 Lorscheider FL, et al. Mercury vapour exposure inhibits tubulin binding to GTP in rat brain:

A molecular lesion also present in human Alzheimer brain. FASEB J, 1995;9(4):3845.


548 Lorscheider FL, et al. Mercury vapour exposure inhibits tubulin binding to GTP in rat brain:

A molecular lesion also present in human Alzheimer brain. FASEB J, 1995;9(4):3845.


549 Pendergrass JC, et al. Mercury vapour inhalation inhibits binding of GTP to tubulin in rat brain: Similarity to a molecular lesion in Alzheimer diseased brain.

Neurotoxicology, 1997;18(2):315-324.


550 Wenstrup D, et al. Trace element imbalances in isolated subcellular fractions of Alzheimer's

disease brains. Brain Res, 1990;12:533(1):125-31.

551 Green KN, et al. Nicotinamide restores cognition in Alzheimer's Disease transgenic mice via

a mechanism involving sirtuin inhibition and selective reduction of Thr231-Phosphotau.

J Neurosci, 2008:28(45):11500-10.


552 Kihira T, et al. ALS-like skin changes in mice on a chronic low-Ca/Mg high-Al diet. J Neurol Sci, 2004;219:7-14.


553 Bar-Sela S, et al. Amyotrophic lateral sclerosis in a battery-factory worker exposed to cadmium. Int J Occup Environ Health, 2001;7:109-112.


554 Bergomi M, et al. Environmental exposure to trace elements and risk of amyotrophic lateral sclerosis: a population-based case-control study. B1036 2002;89:116–123.


555 Qureshi M, et al. Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J. 2008;2:51-4.


556 Levenson CW. Trace metal regulation of neuronal apoptosis: from genes to behavior. Physiol Behav, 2005;86:399-406.


557 Conradi S, et al. Abnormal distribution of lead in amyotrophic lateral sclerosis -reestimation of lead in the cerebrospinal fluid. J Neurol Sci, 1980;48:413-18.


558 Yase Y, et al. Kii ALS dementia. Neuropathology, 2001;21:105-9.


559 Okamoto K, et al. Intracytoplasmic inclusions (Bunina bodies) in amyotrophic lateral sclerosis. Acta Pathol (Jpn), 1980;30:591-7.


560 Praline J, et al. ALS and mercury intoxication: a relationship? Clin Neurol Neurosurg, 2007 Dec;109(10):880-3.


561 Arvidson B. Inorganic mercury is transported from muscular nerve terminals to spinal and brainstem motoneurons. Muscle Nerve, 1992;15:1089–1094.


562 Mitchell JD. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurol Clin, 1987;5(1):43-60.


563 Barber TE. Inorganic mercury intoxication reminiscent of amyotrophic lateral sclerosis. J Occup Med,

1978;20(10):667-9.


564 Mano Y, et al. Amyotrophic lateral sclerosis and mercury--preliminary report. Rinsho Shinkeigaku,

1990;30(11):1275-7.


565 Moriwaka F, et al. Mercury and selenium contents in amyotrophic lateral sclerosis in Hokkaido, the

northernmost island of Japan. J Neurol Sci, 1993;118(1):38-42.


565 Arvidson B. Inorganic mercury is transported from muscular nerve terminals to spinal and brainstem motoneurons. Muscle Nerve, 1992;15:1089–1094.


567 Sillevis Smitt PA, et al. Increased metallothionein in the liver and kidney of patients with amyotrophic lateral sclerosis. Arch Neurol, 1992;49:721–724.


568 Sillevis Smitt PA, et al. Metallothionein immunoreactivity is increased in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett, 1992;144:107–110.


569 Valentine JS. Do oxidatively modified proteins cause ALS? Free Radic Biol Med, 2002;33:1314–1320.


570 Kurtzke JF. Epidemiology of amyotrophic lateral sclerosis. Adv Neurol, 1982;36:281–302.


571 Lilienfeld DE, et al. Rising mortality from motoneuron disease in the USA, 1962–84. Lancet, 1989;1:710–713.


572 Johnson FO, Atchison WD. The role of environmental mercury, lead and pesticide exposure in development of amyotrophic lateral sclerosis. Neurotoxicology, 2009;30(5):761-5.


573 Sienko DG, et al. Amyotrophic lateral sclerosis. A case-control study following detection of a cluster in a small Wisconsin community. Arch Neurol, 1990;47(1):38-41.


574 Dantzig PI. Parkinson's disease, macular degeneration and cutaneous signs of mercury toxicity.
J Occup Environ Med, 2006;48:656.

575 Gorell JM, et al. Occupational exposures to metals as risk factors for Parkinson's disease.

Neurology, 1997;48:650-8.


576 Gorell JM, et al. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology,

1999;18(6):303-8.


577 Carpenter DO. Effects of metals on the nervous system of humans and animals. Int J Occup Med Environ Health, 2001;14(3):209-18.


578 Foo SC, et al. Neurobehavioral effects in occupational chemical exposure. Environ Res, 1993;60(2):267-73.


579 Uversky VN, et al. Metal-triggered structural transformations, aggregation, and fibrillation of human

alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.

J Biol Chem, 2001;276(47):44284-96.


580 Dobson AW, et al. Manganese neurotoxicity. Ann N Y Acad Sci, 2004;1012:115–128.


581 Ngim CH, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology, 1989;8(3):128-41.


582 Ngim CH, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology, 1989;8(3):128-41.


583 Rybicki BA, et al. Parkinson's disease mortality and the industrial use of heavy metals in Michigan.

Mov Disord, 1993;8:87-92.


584 Finkelstein Y, et al. The enigma of parkinsonism in chronic borderline mercury intoxication,

resolved by challenge with penicillamine. Neurotoxicology, 1996;17:291-5.


585 Biernat H, et al. Tremor frequency patterns in mercury vapour exposure, compared with early

Parkinson's disease and essential tremor. Neurotoxicology, 1999;20(6):945-52.


586 Holmstrup P. Oral mucosa and skin reactions related to amalgam. Adv Dent Res, 1992;6:120-4.


587 Holmstrup P. Oral mucosa and skin reactions related to amalgam. Adv Dent Res, 1992;6:120-4.


588 Koch P, Bahmer FA. Oral lesions and symptoms related to metals used in dental restorations: a clinical, allergological, and histologic study. J Am Acad Dermatol, 1999;41(3 Pt 1):422-30.


589 Laeijendecker R, et al. Oral lichen planus and allergy to dental amalgam restorations. Arch Dermatol, 2004; 140(12):1434-8.


590 Henriksson E, et al. Healing of lichenoid reactions following removal of mercury-am. A clinical follow-up. J Clin Periodontol, 1995;22(4):287-94.


591 Finne K, et al. Oral lichen planus and contact allergy to mercury. Int J Oral Surg, 1982;11:236-239.


592 Dunsche A, et al. Oral lichenoid reactions associated with amalgam: improvement after amalgam removal. Br J Dermatol, 2003;148(1):70-6.


593 Camisa C, et al. Contact hypersensitivity to Hg in Hg-am restorations may mimic oral lichen planus. Cutis, 1999:63(3):189-92.


594 Henriksson E, et al. Healing of lichenoid reactions following removal of Hg-am. A clinical follow-up. J Clin Periodontol, 1995;4:287-94.


595 Martin MD, et al. Oral lichen planus and dental materials: a case-control study. Contact Dermatits, 2003;48(6):331-6.


596 Dunsche A, et al. Lichenoid reactions of murine mucosa associated with amalgam. Br J Dermatol, 2003;148(4):741-8.


597 Chase HS. Some observations and experiments connected with oral electricity. Am J Dent Sci, 1878;12:18-23.


598 Rose MD, et al. The tarnished history of a posterior restoration. Br Dent J, 1998;14:185(9):436.


599 Claudia M, et al. Artificial Grasping System for the Paralyzed Hand. International Society for Artificial Organs, 2000;24(3):185-188.


600 Ciszewski A, et al. Corrosion by galvanic coupling between amalgam and different chromium-based

alloys. Dent Mater, 2007;23(10):1256-61.


601 Moberg LE. Corrosion products from dental alloys and effects of mercuric and cupric ions on a neuroeffector system. Swed Dent J Suppl, 1985;29:1-51.


602 Toumelin-Chemla F, et al. Unusual in vivo extensive corrosion of a low-silver Hg amalgam restoration involving galvanic coupling: a case report. Quintessence Int, 2003;34(4):287-94.


603 Moberg LE, Oden A. Long-term corrosion studies in vitro of amalgams in contact. Acta Odontol Scand, 1985;43(4):205-13.


604 Sutow EJ, et al. In vivo galvanic currents of intermittently contacting dental amalgam and other metallic restorations. Dent Mater, 2004;9:823-31.


605 Walker RS, et al. Galvanic interaction between gold and amalgam: effect of zinc, time and surface treatments. JADA, 2003 Nov:134(11):1463-7.


606 Lim SD, et al. Ions released from dental amalgams in contact with titanium. Dent Mater, 2003;22(1):96-110.


607 Schuurs AH, Davidson CL. Amalgam III. Mercury release from amalgam restorations. Ned Tijdschr Tandheelkd, 1993;100(2):45-8.


608 Hugoson A, et al. Results obtained from patients referred for the investigation of complaints related

to oral galvanism. Swed Dental J, 1986;10(1-2):15-28.


609 Procházková J, et al. Metal alloys in the oral cavity as a cause of oral discomfort in sensitive patients.

Neuro Endocrinol Lett, 2006 Suppl;1:53-8.


610 Procházková J, et al. Metal alloys in the oral cavity as a cause of oral discomfort in sensitive patients.

Neuro Endocrinol Lett, 2006 Suppl;1:53-8.


611 Horasawa N, et al. Cyclic voltammetry of dental amalgams. Dent Mater, 1996;12(3):154-60.
612 Ciszewski A, et al. Corrosion by galvanic coupling between amalgam and different chromium-based alloys. Dent Mater, 2007;3(10):1256-61.


613 Kucerová H, et al. Influence of galvanic phenomena on the occurrence of allergic symptoms in the mouth. Gen Dent, 2002;50(1):62-5.


614 Martin MD, et al. Oral lichen planus and dental materials: a case-control study. Contact Dermatitis, 2003;48(6):331-6.


615 Brailo V, et al. Oral burning symptoms and burning mouth syndrome - significance of different variables in 150 patients. Med Oral Patol Oral Cir Bucal, 2006;1:11(3):E252-5.


616 Toumelin-Chemla F, Lasfargues JJ. Unusual in vivo extensive corrosion of a low-silver amalgam restoration involving galvanic coupling: a case report. Quintessence Int, 2003 Apr;34(4):287-94.


617 Hendry WF, et al. Was Young's syndrome caused by exposure to mercury in childhood? BMJ,

1993;307:1579-82.


618 Sheiner EK, et al. Effect of occupational exposures on male fertility: literature review. Ind Health, 2003;41:55–62.


619 Keck C, et al. Autometallographic detection of mercury in testicular tissue of an infertile man exposed to mercury vapour. Toxicol, 1993 Sep-Oct;7(5):469-75.


620 Podzimek S, et al. Effect of heavy metals on immune reactions in patients with infertility.

Cas Lek Cesk, 2003; 142(5):285-8.


621 Ernst E, Lauritsen JG. Effect of organic and inorganic mercury on human sperm motility. Pharmacol Toxicol, 1991:440-4.


622 Laks DR. Assessment of chronic mercury exposure within the U.S. population, National Health and

Nutrition Examination Survey (1999-2006). Biometals, 21 Aug 2009.


623 http://www.ksby.com/Global/story.asp?S=10981098


624 Yang JM, et al. Effects of metallic mercury on the perimenstrual symptoms and menstrual outcomes of exposed workers. Am J Ind Med, 2002;42(5):403-9.


625 Gerhard I. Environmental pollutants and fertility disorders. Heavy metals and minerals. Geburtshilfe Frauenheilkd, 1992; 52(7):383-96.


626 Gerhard I, et al. Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages. Human Reprod Update, 1998;4(3):301-9.


627 Rowland AS, et al. The effect of occupational exposure to mercury vapour on the fertility of female dental assistants. Occup Environ Med, 1994;51(1):28-34.


628 Gerhard I, et al. Heavy metals and fertility. Toxicol Environ Health A, 1998;54(8):593-611.


629 www.treatycouncil.org/new_page_5211421311.htm accessed 2010


630 Cordier S, et al. Paternal exposure to mercury and spontaneous abortions. Br Ind J Med, 1991;48(6):375-81.


631 Ong CN, et al. Concentrations of heavy metals in maternal and umbilical cord blood. Biometals,

1993 Spring; 6(1):61-6.


632 Morgan DL, et al. Disposition of inhaled mercury vapour in pregnant rats: maternal toxicity and effects on developmental outcome. Toxicol Sci, 2002;66(2):261-73.


633 Yoshida M. Placental to fetal transfer of mercury and fetotoxicity. Tohoku J Exp Med, 2002 Feb;196(2):79-88.


634 Abadin HG, et al. Breast-feeding exposure of infants to cadmium, lead, and mercury: a public health viewpoint. Toxicol Ind Health, 1997;13(4):495-517.


635 Yang J, et al. Maternal-fetal transfer of metallic mercury via the placenta and milk.

Ann Clin Lab Sci, 1997 Mar-Apr;27(2):135-41.


636 Drexler H, Schaller KH. The mercury concentration in breast milk resulting from amalgam fillings and dietary habits. Environ Res, 1998;77(2):124-9.


637 Kuhnert PM, et al. Comparison of mercury levels in maternal blood, fetal cord blood, and

placental tissues. Am J Obstet Gynecol, 1981 Jan 15;139(2):209-13.


638 Kukizaki S, et al. Studies on the effects of dental amalgam upon the fertilization and early development of sea urchin eggs (Hemicentrotus pulcherrimus) Shika Rikogaku Zasshi, 1975;16(35):123-37.


639 Hahn LJ, et al. Dental "silver" tooth fillings: a source of mercury exposure revealed by whole-body image scan and tissue analysis. FASEB J, 1989;3(14):2641-6.


640 Vimy MJ, et al. Maternal-fetal distribution of mercury (203Hg) released from dental amalgam fillings. Am J Physiol, 1990 Apr;258(4 Pt 2):R939-45.


641 Yoshida M. Placental to fetal transfer of mercury and fetotoxicity. Tohoku J Exp Med, 2002 Feb;196(2):79-88.


642 Hahn LJ, et al. Whole-body imaging of the distribution of mercury released from dental fillings into

monkey tissues. FASEB J, 1990 Nov;4(14):3256-60


643 Oskarsson A, et al. Total and inorganic mercury in breast milk in relation to fish consumption and amalgam in lactating women. Arch Environ Health, 1996 May-Jun;51(3):234-41.


644 Schumann K. The toxicological estimation of the heavy metal content (Cd, Hg, Pb) in food for infants and small children. Z Ernahrungswiss, 1990;29(1):54-73.


645 Schumann K. The toxicological estimation of the heavy metal content (Cd, Hg, Pb) in food for infants and small children. Z Ernahrungswiss, 1990;29(1):54-73.


646 Vahter M, et al. Longitudinal study of methyl mercury and inorganic mercury in blood and urine of pregnant and lactating women, as well as in umbilical cord blood. Environ Res, 2000;84(2):186-94.


647 Bjornberg KA, et al. Methyl mercury and inorganic mercury in Swedish pregnant women and in cord blood: influence of fish consumption. Environ Health Perspect, 2003;111(4):637-41.


648 Takahashi Y, et al. Placental transfer of mercury in pregnant rats which received dental amalgam restorations. Toxicology, 2003;185(1-2):23-33.


649 Drasch G, et al. Mercury burden of human fetal and infant tissues. Eur J Pediatr, 1994,153(8):607-10.


650 Drasch G, et al. Mercury in human colostrum and early breast milk. Its dependence on dental amalgam and other factors.Trace Elem Med Biol, 1998;12(1):23-7.


651 Razagui IB, Haswell SJ. Mercury and selenium concentrations in maternal and neonatal scalp hair: relationship to amalgam-based dental treatment received during pregnancy. Elem Res, 2001;81(1):1-19.


652 Lindbohm ML, Ylöstalo P, et al. Occupational exposure in dentistry and miscarriage. Occup Environ Med, 2007,64(2):127-33.


653 Elghany NA, et al. Occupational exposure to inorganic mercury vapour and reproductive outcomes. Occup Med (Lond). 1997;47(6):333-6.


654 Gordon H, et al. Pregnancy in female dentists: A mercury Hazard. In: Proceedings of International Conference on Mercury Hazards in Dental Practice. Glasgow, Scotland 1981, 2-4


655 Gerhard I, et al. Heavy Metals and Fertility. J Toxicol Environ Health, 1998;54(8):593-611.


656 Lee IP, et al. Effects of environmental metals on male reproduction. In: Reproduction and Developmental Toxicity of Metals. Plenum Press, NY, 1983:253-78.


657 Panova Z, et al. Ovarian function in women having professional contact with metallic mercury. Akusherstvoi Ginekologiya, 1974:29-34.


658 Newland MC, et al. Prolonged behavioral effects of in utero exposure to lead or methyl mercury: reduced sensitivity to changes in reinforcement contingencies during behavioral transitions and in steady state. Toxicol Appl Pharmacol, 1994;126(1):6-15.


659 Mjor IA, Pakhomov GN. Dental amalgam and alternative direct restorative materials, WHO, Division of Noncommunicable Diseases, Geneva, 1997.


660 Centers for Disease Control and Prevention (CDC). Blood and hair mercury levels in young children and women of childbearing age - United States, 1999. MMWR Morb Mortal Wkly Rep, 2001; 50:140-3.


661 Warfinge K, et al. The effect on pregnancy outcome and fetal brain development of prenatal exposure to mercury vapour. Neurotoxicology, 1994;5(4).


662 Lutz E, et al. Concentrations of mercury, cadmium and lead in brain and kidney of second trimester foetuses and infants. Trace Elem Med Biol, 1996;10(2):61-7.


663 Grandjean P, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methyl mercury. Neurotoxicol Teratol, 1997;19(6):417-28.


664 Lutz E, et al. Concentrations of mercury, cadmium and lead in brain and kidney of second trimester foetuses and infants.Trace Elem Med Biol, 1996;10(2):61-7.


665 Urbach J, et al. Effect of inorganic mercury on in vitro placental nutrient transfer and oxygen consumption. Reprod Toxicol, 1992;6(1):69-75.


666 Mendola P, et al. Environmental factors associated with a spectrum of neurodevelopmental deficits. Ment Retard Dev Disabil Res Rev, 2002;8(3):188-97.


667 Kakita A, et al. Intrauterine methyl mercury intoxication. Consequence of the inherent brain lesions and cognitive dysfunction in maturity. Brain Res, 2000;877(2):322-30.


668 Boadi WY, et al. In vitro effect of mercury on enzyme activities and its accumulation in the first-trimester human placenta. Environ Res, 1992 Feb;57(1):96-106.


669 Fredriksson A, et al. Prenatal coexposure to metallic mercury vapour and methyl mercury produce

interactive behavioural changes in adult rats. Neurotoxicol Teratol, 1996;(2):129-34.


670 Yoshida M. Tohoku J. Placental to fetal transfer of mercury and fetotoxicity. Exp Med, 2002;196(2):79-88.


671 Ramirez GB, et al. Tagum study II: follow-up study at two years of age after prenatal exposure to

mercury. Pediatrics, 2003;111(3):e289-95.


672 Soderstrom S, et al. The effect of mercury vapour on cholinergic neurons in the fetal brain: studies on the expression of nerve growth factor and its low- and high-affinity receptors. Brain Res Dev Brain Res, 1995;85(1):96-108.


673 Warfinge K, et al. The effect on pregnancy outcome and fetal brain development of prenatal exposure to mercury vapour. Neurotoxicology, 1994:15(4): Pages??


674 Geier MR, Geier DA. The potential importance of steroids in the treatment of autistic spectrum

disorders and other disorders involving mercury toxicity. 2005;64(5):946-54.


675 McGuireT. The poison in your teeth. The Dental Wellness Institute, Sebastopol. 2008. ISBN 978-0-9815630-0-8


676 Geier MR, Geier DA. The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses, 2005;64(5):946-54.


677 Holmes AS, et al. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol, 2003;22: 277-85.


678 McGuire T. The poison in your teeth. The Dental Wellness Institute, Sebastopol, 2008. ISBN 978-0-9815630-0-8.


679 Pizzichini M, et al. Release of mercury from dental amalgam and its influence on salivary antioxidant

activity. Sci Total Environ, 2002 Feb 4;284(1-3):19-25.


680 Leistevuo J, et al. Mercury in saliva and the risk of exceeding limits for sewage in relation to exposure to amalgam fillings. Arch Environ Health, 2002 Jul-Aug;57(4):366-70.


681 Drouet M, et al. Is mercury a respiratory tract allergen? Allerg Immunol, 1990;22(3):81.


682 Yoshida S, et al. Amalgam allergy associated with exacerbation of aspirin-intolerant asthma. Clin Exp Allergy, 1999; 29(10): 1412-4.


683 Kidd RF. Results of dental amalgam removal and mercury detoxification using DMPS and neural therapy. Altern Ther Health Med, 2000 Jul; 6(4):49-55.


684 Jones L. Dental Amalgam and Health Experience: Exploring Health Outcomes and Issues for People Medically Diagnosed with Mercury Poisoning. The Bulletin of the New Zealand Psychological Society, 1999;97:29-33.


685 Zamm AV. Dental mercury: A factor that aggravates and induces xenobiotic intolerance. J Orthomolec Med, 1991;6(2):67-77.


686 Lichtenberg HJ. Elimination of symptoms by removal of dental amalgam from mercury poisoned patients, as compared with a control group of average patients. J Orthomolec Med, 1993;8:145-148.


687 Stenman S, Grans L. Symptoms and differential diagnosis of patients fearing mercury toxicity

from amalgam fillings. Scand J Work Environ Health, 1997; 23 Suppl 3:59-63.


688 Lichtenberg HJ. Symptoms before and after proper amalgam removal in relation to serum-globulin reaction to metals. J Orthomolec Med, 1996:11:195-204.


689 Siblerud RL. The relationship between mercury from dental amalgam and mental health. Am J Psychother,

1989 Oct; 43(4):575-87.


690 Lygre GB, et al. A follow-up study of patients with subjective symptoms related to dental materials. Community Dent Oral Epidemiol, 2005 Jun;33(3):227-34.


691 Lindh U, et al. Removal of dental amalgam and other metal alloys supported by antioxidant therapy alleviates symptoms and improves quality of life in patients with amalgam-associated ill health. Neuro Endocrinol Lett, 2002 Oct-Dec;23(5-6):459-82.


692 Ziff MF. Documentated clinical side-effects to dental amalgam. Adv Dent Res, 1992;6:131-4.


693 Ziff MF. Documentated clinical side-effects to dental amalgam. Adv Dent Res, 1992;6:131-4.


694 Kage M, et al. Cytotoxicity of Amalgams. J Dent Res, 1988;67(9):1221-4.


695 http://www.ccrlab.com


696 Huggins H. It’s all in your head. p88


697 Smith RG, et al. Effects of exposure to mercury in the manufacture of chlorine. Am Ind Hyg

Assoc J, 1970;31: 687-700.


698 Clarkson TW, et al. Public Health Consequences of Heavy Metals in Dump Sites. Environmental

Health Perspectives, 1983;48:113-127.


699 Cherian M G, et al. Radioactive mercury distribution in biological fluids and excretion in human subjects after inhalation of mercury vapor. Arch Environ Health, 1978;33: 109-114.


700 Clarkson TW, et al. Public Health Consequences of Heavy Metals in Dump Sites. Environmental Health Perspectives, 1983;48:113-127.


701 Hursh JB, et al. Clearance ofmercury (Hg-197, Hg-203) vapor inhaled by human subjects. Arch Environ Health, 1976;31:302-309.


702 Clarkson TW. The three modern faces of mercury. Environ Health Perspect, 2002;110(1):11–23.


703 Risher J, Dewoskin R. Toxicological profile for Mercury. In: B1181Services, U.D. O. H. A. H. (Ed.), Agency for Toxic Substances and Disease Registry, 1999.


704 Risher JF, Amler SN. Mercury exposure: evaluation and intervention the inappropriate use of chelating agents in the diagnosis and treatment of putative mercury poisoning. Neurotoxicology, 2005; 26:691–699.


705 Vahter M, et al. Speciation of mercury in the primate blood and brain following long-term exposure to methyl mercury. Toxicol Appl Pharmacol, 1994;124: 221–229.


706 Opitz H, et al. Demonstration of mercury in the human brain and other organs 17 years after metallic mercury exposure. Clin Neuropathol, 1996;15:139–144.


707 Hargreaves RJ, et al. Persistent mercury in nerve cells 16 years after metallic mercury poisoning. Neuropathol Appl Neurobiol, 1988;14:443–452.


708 Nordberg GF. Effects and Dose-Response Relationships of Toxic Metals. Scand J Work Environ Health,

1976 Mar;2(1):37-43.


709 Ely JTA. Mercury induced Alzheimer’s Disease: accelerating incidence? Bull Environ Contam Toxicol, 2001;67:800-806.


710 McNerney RT, Mcnerney, JJ. A review. Mercury contamination in the dental office. NYS Dent J, 1979;45(9):457-458.


711 Ely JTA. Mercury induced Alzheimer’s Disease: accelerating incidence? Bull Environ Contam Toxicol, 2001;67:800-6.


712 Queen S. Chronic Mercury Toxicity - New Hope Against an Endemic Disease. Bioprobe. http://www.bioprobe.com.


713 Lorscheider FL, et al. Mercury exposure from silver tooth fillings: emerging evidence questions a paradigm. FASEB J, 1995;9:504-508.


714 Goldwater LJ. Toxicology of Inorganic Mercury. Annals NY Acad Sci, 1957;65:498-503.


715 Nielsen JB, et al. Evaluation of mercury in hair & blood as biomarkers for methyl mercury exposure. Arch of Toxicology, 1994;65(5):317-321.


716 World Health Organization (WHO) 1990, Environmental Health Criteria vol 101, Methyl Mercury, WHO, Geneva.


717 World Health Organization (WHO) 1991, Environmental Health Criteria vol 118, Inorganic Mercury, WHO, Geneva.


718 Arena & Drew. Toxicology – Symptoms - Treatment. Poisoning. Fifth Edition. Charles C. Thomas, Springfield, Il. 1986.


719 Goyer RA. Toxic effects of metals IN: Caserett and Doull’s Toxicology – The Basic Science of

Poisons, McGraw-Hill Inc, NY. 1993; &

Goodman & Gillman. The Pharmacological Basis of Therapeutics, Mac Millan Publishing Company,

NY, 1985.


720 Skuba A. Survey for Mercury vapor in Manitoba dental offices. J Can Dent Assoc, 1984;50(7):517?522.


721 Roydhouse RH, et al. Mercury in dental offices. J Can Dent Assoc, 1985;51(2):156?8.


722 McNerney RT, McNerney JJ. Mercury Contamination in the Dental Office: A Review. NY State Dental Journal, 1979;45(9):457-458.


723 Miller RW, et al. Report on Independent survey taken of Austin dental offices for mercury contamination. Texas Dent J, 1983;100(1):6?9.


724 Schulein TM, et al. Survey of Des Moines area dental offices for mercury vapor. Iowa Dent J, 1984;70(1):35?6; & Jones DW, et al. Survey of Mercury vapor in dental offices in Atlantic Canada. Can Dent Assoc J, 1983;4906:378?395.


725 Opitz H, et al. Demonstration of mercury in the human brain and other organs 17 years after metallic mercury exposure. Clin Neuropathol, 1996;15:139–144.


726 Ahlquist M, et al. Number of amalgam tooth fillings in relation to subjectively experienced symptoms in a study of Swedish women. Community Dent Oral Epidemiol, 1988;16(4):227-231.


727 Lavstedt S, Sundberg H. Medical diagnoses and symptoms related to amalgam fillings. Tandlakartid, 1989;81:81-8.


728 National Institute of Dental Research. Workshop:biocompatibility of metals in dentistry. JADA, 1984;109:469-471.


729 Drasch G, et al. Are blood, urine, hair, and muscle valid bio-monitoring parameters for the internal burden of men with the heavy metals mercury, lead and cadmium? Trace Element Electrolytes, 1997;14:116–123.


730 Danscher G, et al. Traces of mercury in organs from primates with amalgam fillings. Exp Mol Pathol, 1990;52:291–9.


731 Hahn LJ, et al. Dental “silver” tooth fillings: A source of mercury exposure revealed by whole-body

image scan and tissue analysis. FASEB J, 1989;3:2641–6.


732 Hahn LJ, et al. Whole-body imaging of the distribution of mercury released from dental fillings into monkey tissues. FASEB J, 1990;4:3256–3260.


733 Hargreaves RJ, et al. Persistant mercury in nerve cells 16 years after metallic mercury poisoning. Neuropathol Appl Neurobiol, 1988;14:443–452.


734 Holmes AS, et al. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol, 2003;22:277–285.


735 Opitz H, et al. Demonstration of mercury in the human brain and other organs 17 years after metallic mercury exposure. Clin Neuropathol, 1996;15:139–144.


736 Vimy MJ, et al. Maternal–fetal distribution of mercury (203 Hg) released from dental amalgam fillings. Am J Physiol, 1990;258:939–945.


737 Weiner JA, Nylander M. The relationship between mercury concentration in human organs and different predictor variables. Sci Total Environ, 1993;138:101–115.


738 Drasch G, et al. Response to the letter of the Human Biomonitoring Commission. Int J Hyg Environ Health, 2004;207:183–4.


739 Drasch G, et al. Scientific comment on the German human biological monitoring values (HBM values) for mercury. Int J Hyg Environ Health, 2002;205:509–512.


740 Drasch G, et al. The Mt. Diwata study on the Philippines 1999 — Assessing mercury intoxication of the population by small scale gold mning. Sci Total Environ, 2001;267:151–168.


741 Neal PA, Jones R. Chronic mercurialism in the hatter’s fur-cutting industry. JAMA, 1938;110:337-343.


742 James S et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr, 2004;80:1611-7.


743 Mutter J et al. Comments on the Article “The Toxicology of Hg and its Chemical Compounds” by Clarkson and Magos (2006). Critical Reviews in Toxicology, 2007;37:537-549.


744 World Health Organization. Mercury in Health Care. Policy Paper, August 2005. www.who.int/water sanitation health/medicalwaste/mercurypolpaper.pdf.


745 Bland J. Medical Symptoms Questionnaire. © 1997 Metagenics, Inc and Immuno Laboratories, Inc.


746 Blaurock-Busch E. Hair mineral analysis: a review and update based on current research. Townsend Letter, 1 May 2008.


747 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5343a5.htm#tab1.


748 Stejskal VDM, et al. Mercury-specific lymphocytes: An indication of mercury allergy in man. J Clinical Immunology, 1996;16(1):31-40.


749 http://www.melisa.org/


750 www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm173992.htm


751 Stejskal VD, et al. Mercury-specific lymphocytes: an indication of mercury allergy in man. J Clinical Immunology, 1996;16(1):31-40.


752 Barber TE, Wallis G. Correction of urinary mercury concentration by specific gravity, osmolality, and creatinine. J Occup Med, 1986 May;28(5):354-9.


753 Kroncke A, et al. Uber die Quecksilberkonzentrationen in Blut und Urin von Personen mit und ohne Amalgamfuillungen. Dtsch Zahndrztl Z, 1980;35:803-808.


754 Olstad ML, et al. Correlation between amalgam restorations and Hg concentrations in urine. J Dent Res, 1987;66:1179-1182.


755 Personal email correspondence with Dr.E.Blaurock-Busch PhD, director of Micro Trace Minerals, 11 February 2010.


756 Heyer NJ, et al. Reply to the Letter to the Editor: Response to comment on: “ A cascade analysis of the interaction of mercury and coproporphyrinogen oxidase (CPOX) polymorphism on the heme biosynthetic pathway and porphyrin production” by Heyer et al. [Toxicol. Lett. 1612006 159–166]. Toxicol Lett. 2007 Feb 28;169(1):93-94.


757 Barr DB, et al. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect, 2005 Feb;113(2):192-200.


758 Barr DB, et al. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect, 2005 Feb;113(2):192-200.


759 Zalups RK. Molecular interactions with mercury in the kidney. Pharmacol Rev, 2000 Mar;52(1):113-43.


760 Campbell N, Godfrey M. Confirmation of Mercury Retention and Toxicity using DMPS provocation. J Advancement Medicine,1994;7(1).


761 Clarkson TW et al. The prediction of intake of mercury vapor from amalgams, in Biological Monitoring of Toxic Metals. Plenum Press, NY, 1988:199-246 & p247-260.


762 Woods JS et al. Altered porphyrin metabolites as a biomarker of mercury exposure and toxicity. Physiol Pharmocol, 1996;74(2):210-15.


763 Woods JS et al. Urinary porphyrin profiles as biomarker of mercury exposure: studies on dentists. J Toxicol Environ Health, 1993;40(2-3):235.

Martin MD et al. The validity of spot urine samples for low-level occupational mercury exposure assessment and relationship to porphyrin and creatinine excretion rates. J Pharmacol Exp Ther, 1996;277(1):239-244.

Woods JS et al. Effects of Porphyrinogenic Metals on Coproporphrinogen Oxidase in Liver and Kidney. Toxicology and Applied Pharmacology, 1989;97:183-190.

Strubelt O, et al. Comparative studies on the toxicity of mercury, cadmium, and copper toward the isolated perfused rat liver. J Toxicol Environ Health, 1996;47(3):267-83.

Kaliman PA, et al. Regulation of heme oxygenase activity in rat liver during oxidative stress induced by cobalt chloride and mercury chloride. Biochemistry(Mosc), 2001;66(1):77-82.

Kumar SV, et al. In vitro binding of inorganic mercury to the plasma membrane of rat platelet affects Na+-K+-Atpase activity and platelet aggregation. Biometals, 2002;15(1):51-7.

Heyer NJ, et al. A cascade analysis of the interaction of mercury and coproporphyrinogen oxidase (CPOX) polymorphism on the heme biosynthetic pathway and porphyrin production. Toxicol Lett, 2006;161(2):159-66.


764 Rupp NW, Paffenberger, GC. Significance to health of mercury used in dental practice. Reports of Councils and Bureaus, JADA, 1971;82(6):1401-7.


765 Bellinger DC, et. al. Neuropsychological and renal effects of dental amalgam in children. JAMA, 2006;295(15):1775-83.


766 DeRouen TA, et al. Neurobehavioral effects of dental amalgam in children. JAMA, 2006;295(15):784-92.


767 Bellinger DC, et. al. Neuropsychological and renal effects of dental amalgam in children. JAMA, 2006;295(15):1775-83.


768 DeRouen TA, et al. Neurobehavioral effects of dental amalgam in children. JAMA, 2006;295(15):784-92.


769 Guzzi G, et al. Mercury and dental patients: toxicology, immunology and genetic connection. Toxicol Lett, 2005; 158S: S239.


770 Needleman H. Mercury in dental amalgam - a neurotoxic risk? JAMA, 2006:295(15):1035-6.

http://www.iaomt.org/articles/files/files280/Needleman%20editorial.pdf.


771 Barregard L, et al. Renal effects of dental amalgam in children: the New England children's amalgam trial.  Environ Health Perspect, 2008 Mar;116(3):394-9.


772 Torres-Alanis O, et al. Urinary excretion of trace elements in humans after sodium 2,3-dimercaptopropane-1-sulfonate challenge test. J Toxicol Clin Toxicol, 2000;38(7):697-700.


773 Aposhian HV, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology, 1995 Mar 31; 97(1-3):23-38.


774 Ruprecht J. Dimaval Scientific monograph, 6th Ed, Heyl Corporation. Jan 1997.


775 Aposhian HV, et al. Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid: correlation with dental amalgam score. FASEB J, 1992;6(4):2472–6.


776 Juresa D, et al. Simultaneous administration of sodium selenite and mercuric chloride decreases efficacy of DMSA and DMPS in mercury elimination in rats. Toxicol Lett, 2005 Jan 15;155(1):97-102.


777 Aposhian HV, et al. Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to mercury vapor. J Toxicol Clin Toxicol, 2003;41:339–347.


778 Buchet JP, Lauwerys RR. Influence of 2,3- dimercaptopropane-1-sulfonate and dimercaptosuccinic acid on the mobilization of mercury from tissues of rats pretreated with mercuric chloride, phenylmercury acetate or mercury vapors. Toxicology, 1989;54:323–333.


779 George GN, et al. Mercury binding to the chelation therapy agentsDMSAandDMPSand the rational design of custom chelators for mercury. Chem Res Toxicol, 2004;17: 999–1006.


780 Aaseth J, Frieheim EA.Treatment of methyl mercury poisoning in mice with 2,3-dimercaptosuccinic

acid and other complexing thiols. Acta Pharmacol Toxicol (Copenh), 1978 Apr;42(4):248-52.


781 Campbell N, Godfrey M. Confirmation of Mercury Retention and Toxicity using DMPS provocation. J Advancement in Medicine,1994;7(1).


782 Echeverria D, et al. Chronic low-level mercury exposure, BDNF polymorphism, and associations with cognitive and motor function. Neurotoxicol Teratol, 2005 Nov-Dec;27(6):781-96.


783 Echeverria D, et al. Neurobehavioral effects from exposure to dental amalgam: new distinctions between recent exposure and mercury body burden. FASEB J, 1998;12(11):971-980.


784 Campbell N, Godfrey M. Confirmation of Mercury Retention and Toxicity using DMPS provocation. J Advancement in Medicine,1994;7(1).


785 Nilsson B et al. Urinary mercury excretion in dental personnel. Swed Dent J, 1986;10(6):221-32.


786 Zander D, et al. Mercury exposure of male dentists, female dentists, and dental aides. Zentralbl Hyg Umweltmed, 1992;193(4):318-28.


787 Daunderer M. Handbuch der Amalgamvergiftung, Ecomed Verlag, Landsberg 1998, ISBN 3?609?71750?5.


788 Daunderer M, et al. Quecksilber, Methylquecksilber, in Korpermaterial von Amalgamtrager. Klin Lab 38, 1992;391-403.


789 Schiele R, et al. Studies of organ mercury content related to number of amalgam fillings. Symposium paper, March 12, 1984, Cologne, Germany.


790 Aposhian HV, et al. Human studies with the chelating agents, DMPS and DMSA. Clinical Toxicology, 1992;30(4):505-528.


791 Osterblad O, et al. Antimicrobial and mercury resistance among persons with and without amalgam fillings. Antimicrobial Agents and Chem, 1995;39(11):2499.


792 Denton, S. The Mercury Cover-Up: Controversies in Dentistry. Townsend Letter For Doctors,

July 1990;488-491.

Denton S, Butler J. Dept. of Psychology, Univ. Of North Texas, Proceedings of the First

International Conference on Biocompatibility, Life Sciences Press, Oct 1990:133-45.


793 Skare I, et al. Human Exposure to Hg and Ag Released from Dental Amalgam Restorations. Arch Environ Health, 1994;49(5):384-94.


794 NIDR/ADA Workshop, Biocompatibility of Metals in Dentistry. JADA, 1984;109(3):469-471.


795 Engqvist A, et al. Speciation of mercury excreted in feces from individuals with amalgam fillings. Arch Environ Health, 1998;53(3):205-13.


796 Great Smokies Diagnostic Lab, research web pages (by condition) http://www.gsdl.com.Doctors Data Inc Lab, http://www.doctorsdata.com, This e-mail address is being protected from spambots. You need JavaScript enabled to view it , www.doctorsdata.com. MetaMetrix Lab, www.metametrix.com.


797 Doctors Data Inc. Fecal Elements Test. P.O.Box 111, West Chicago, Illinois, 60186-0111. www.doctorsdata.com.


798 Malmström C, et al. Conference on Trace Elements in Health and Disease. Stockholm. May 25,1992; &

Malmstrom C, et al. Silver amalgam: an unstable material. Swedish paper translated in Bio-Probe Newsletter, 1993;9(1):5-6; &

http://home.swipnet.se/misac/research1.html.

Malmstrom C. Amalgam derived mercury in feces. J Trace Elements Exper Med, 1992;5:122; &

http://home.swipnet.se/misac/research7.html; &

Nylander M, et al. Fourth international symposium Epidemiology in Occupational Health. Como Italy Sept 1985; &

http://home.swipnet.se/misac/infpatient.html.


799 Osterblad M, et al. Antimicrobial and mercury resistance in aerobic gram-negative bacilli in fecal flora among persons with and without dental amalgam fillings. Antimicrob Agents Chemother, 1995 Nov;39(11):2499-502.


800 ASTDR ToxFAQ CAS# 7439-97-6.


801 Skare I, Engqvist A. Human exposure to mercury and silver released from dental amalgam. Arch Environ Health, 1994;49(5):384-94.


802 Skerfving S. Methylmercury exposure, mercury levels in blood and hair, and health status in Swedes

consuming contaminated fish. Toxicology, 1974;2:3-23.


803 Bass DA, et al. Trace element analysis in hair: Factors determining accuracy, precision, and reliability. Alternat Med Rev, Oct 2001;6(5):472-488.


804 Airey D. Mercury in human hair: a review. Environ Health Perspectives, 1983.52:303-316.


805 Gonzalez MJ, et al. Mercury in human hair; residents of Madrid, Spain. Arch Environ Health, 1985;40(4):225-8.


806 Airey D. Total mercury concentrations in human hair from 13 countries. Sci Total Environ, 1983;32(2):157-80.


807 Katz SA, et al. Use of hair analysis for evaluating mercury intoxication of the human body. J Appl Toxicol, 1992;12(2):79-84.


808 Wilhelm M, et al. Biological monitoring of mercury vapor exposure by scalp hair analysis in comparison to blood and urine. Toxicol Lett, 1996;88(1?3):221?6.


809 Biological Monitoring of Toxic Trace Metals, Biological Monitoring and Surveillance, U.S. EPA. Sept 1980;1:3.


810 Amin-Zaki L, et al. Perinatal methyl mercury poisoning in Iraq. Am J Dis Child, 1976;130:1070-6.


811 Wheatley B. Methylmercury in Canada. Exposure of Indian and Inuit residents to methylmercury in the

Canadian environment. Medical Services Branch, Ministryof National Health and Welfare, Ottawa, Canada, 1979.


812 Suzuki T, et al. The hair-organ relationship in mercury concentration in contemporary Japanese. Arch Environ Health, 1993;48(4):221-9.


813 Schweinsberg F. Risk estimation of mercury intake from different sources. Toxicol Lett, 1994;72:45-51.

Pzheusskaia LD. Disintoxication therapy of patients with nonspecific inflammatory diseases of the female genital organs. Akush Ginekol, 1977;4:30-34.


814 Holmes AS, et al. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol, 2003;22(4):277-85.


815 Wecker L et al. Trace element concentrations in hair from autistic children. J Ment Defic Res, 1985;29(Pt 1):15-22.


816 LeBlanc A, et al. Trace element content of commercial shampoos: impact on trace element levels in hair. Sci Total Environ, 1999;229:121-124.


817 Shamberger RJ. Validity of hair mineral testing. Biol Trace Elem Res, 2001 Jun;87(1-3):1-28.


818 Ryabukhin YS. Activation analysis of hair as an indicator of contamination of man by environmental trace element pollutants. IAEA Report, Vienna, 1978.


819 Ryabukhin YS. Nuclear-based methods for the analysis of trace element pollutants in human hair. J Radioanal Chem, 1980;60:7-30.


820 Samanta G, et al. Arsenic and other elements in hair, nails and skin scales of arsenic victims in West Bengal, India. Sci Total Environ, 2004 Jun 29;326(1):33-47.


821 Drasch G, Roider G. Assessment of hair mineral analysis commercially offered in Germany. J Trace Elem Med Biol, 2002;16(1):27-31.


822 Seidel S, et al. Assessment of commercial laboratories performing hair mineral analysis. JAMA,

2001 Jan 3;285(1):67-72.


823 Monaci F, et al. Concentrations of major elements and mercury in unstimulated human saliva. Biol Trace Elem Res, 2002 Dec;89(3):193-203.


824 Kraub P, et al. Field Study on the mercury content of saliva. Heavy Metal Bull, 1996;3(1).

http://www.xs4all.nl/~stgvisie/AMALGAM/EN/SCIENCE/tubingen.html.


825 Monaci F, et al. Concentrations of major elements and mercury in unstimulated human saliva. Biol Trace Elem Res, 2002 Dec;89(3):193-203.


826 Motorkina AV, et aI. Mercury release from amalgam fillings into oral cavity. Stomatologia (Mosk), 1997;76(4):9-11.


827 Utt HD. Mercury Breath. J Calif Dental Assoc, 1984;12(2):41.


828 Vimy MJ, Lorscheider FL. Intraoral air mercury released from dental amalgam. J Dent Res, 1985;64:1069-71.


829 Vimy MJ, Lorscheider FL. Serial measurements of intraoral air mercury: estimation of daily dose from dental amalgam. J Dent Res, 1985 Aug;64(8):1072-5.


830 Vimy MJ, Lorscheider FL. Estimation of mercury body burden from dental amalgam: Computer simulation of a metabolic compartmental model. J Dent Res, 1986;65(12):1415-1419.


831 Woods JS. Altered porphyrin metabolism as a biomarker of mercury exposure and toxicity. Can J Physiol Pharmacol, Feb 1996;74(2):210-5.


832 Pingree SD, et al. Quantitative evaluation of urinary porphyrins as a measure of kidney mercury content and mercury body burden during prolonged methylmercury exposure in rats. Toxicol Sci, 2001; 61:234-40.


833 Woods JS, et al. Urinary porphyrin profiles as a biomarker of mercury exposure: studies on dentists with occupational exposure to mercury vapor. J Toxicol Environ Health, 1993;40:235-46.


834 Echeverria D, et al. Behavioural effects of low-level exposure to elemental Hg among dentists. Neurotoxicol Teratol, 1995;17:161-8.


835 Geier D, Geier M. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotoxicol Res, 2006:10;57-64.


836 Nataf R, et al. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol, 2006; 214 :99-108.


837 Geier D, Geier M. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotoxicol Res, 2006:10;57-64.


838 Nataf R, et al. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol, 2006; 214 :99-108.


839 Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. J Toxicol Environ Health A, 2007;70(20):1723-30.


840 Godfrey ME, et al. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. J Alzheimer’s Disease, 2003; 5(3);189-195.


841 Stejskal VD, et al. Mercury-specific lymphocytes: an indication of mercury allergy in man. J Clin Immunol, 1996;16(1):31-40.


842 Heyer NJ, et al. The association between serotonin transporter gene promoter polymorphism (5-HTTLPR), self-reported symptoms, and dental mercury exposure. J Toxicol Environ Health A. 2008; 71(19): 1318–1326.


843 Andersen O, Aaseth J. Molecular mechanisms of in vivo metal chelation: implications for clinical treatment of metal intoxications. Environ Health Perspect, 2002 Oct;110(5):887-90.


844 Andersen O. Oral cadmium exposure in mice: toxicokinetics and efficiency of chelating agents. CRC Crit Rev Toxicol, 1989;20:83-112.


845 Andersen O. Choice of chelating antidotes for acute cadmium intoxication. Toxicol Environ Chem, 1989;23:105-120.


846 Blan?a M, et al. Chelators as Antidotes of Metal Toxicity: Therapeutic and Experimental Aspects. Current Medicinal Chemistry, 2005;12:2771-94.


847 Klimmek R, et al. Acute effects of the heavy metal antidotes DMPS and DMSA on circulation, respiration, and blood homoeostasis in dogs. Arch Toxicol, 1993; 67(6):428-34.


848 Van der Linde AA, et al. Stevens-Johnson syndrome in a child with chronic mercury exposure and 2,3-dimercaptopropane-1-sulfonate (DMPS) therapy. Clin Toxicol (Phila), 2008 Jun;46(5):479-81.


849 Gersl V, et al. Effects of repeated administration of dithiol chelating agent -

sodium 2,3-dimercapto-1-propanesulphonate (DMPS) - on biochemical and haematological

parameters in rabbits. Acta Medica (Hradec Kralove), 1997;40(1):3-8.


850 Torres-Alanís O, et al. Urinary excretion of trace elements in humans after sodium 2,3-dimercaptopropane-1-sulfonate challenge test. J Toxicol Clin Toxicol, 2000;38(7):697-700.


851 Blanusa M et al. Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Curr Med Chem, 2005;12(23):2771-94.


852 Flora SJ, et al. Heavy metal induced oxidative stress & its possible reversal by chelation therapy. Indian J Med Res, 2008 Oct;128(4):501-23.


853 Miller AL. Dimercaptosuccinic acid (DMSA), a non-toxic, water-soluble treatment for heavy metal toxicity. Altern Med Rev, 1998 Jun; 3(3):199-207.


854 Blanusa M, et al. Inorganic mercury exposure, mercury-copper interaction, and DMPS treatment in rats. Environ Health Perspect, 1994 Sep;102(3):305-7.


855 Sällsten G, et al. Clearance half life of mercury in urine after the cessation of long term occupational exposure: influence of a chelating agent (DMPS) on excretion of mercury in urine. Occup Environ Med, 1994 May;51(5):337-42.


856 Patterson JE, et al. Mercury in human breath from dental amalgams. Bull Environ Contam Toxicol, 1985;34(4):459–68.


857 Hursh JB, et al. Clearance of mercury (HG-197,HG-203) vapor inhaled by human subjects. Arch Environ Health, 1976;31(6):302–9.


858 Björkman L, et al. Mercury in human brain, blood, muscle and toenails in relation to exposure: an autopsy study. Environ Health, 2007;6:30.


859 Van Der Schaar PJ. Clinical Metal Toxicology. IBCMT 5th ed. Holland. 2006.


860 Guzzi G, La Porta C. Molecular mechanisms triggered by mercury. Toxicology, 2008;244:1-12.


861 www.DMPSbackfire.com.


862 Van Der Schaar PJ. Clinical Metal Toxicology. IBCMT 5th ed. Holland. 2006.
863 Gabard B. Improvement of oral chelation treatment of methyl mercury poisoning in rats. Acta Pharmacol Toxicol (Copenh), 1976 Aug;39(2):250-5.


864 Gabard, B. Distribution and excretion of the mercury chelating agent sodium 2,3-dimercaptopropane-1-sulfonate in the rat. Arch Toxicol, 1978;39(4):289-98.


865 Gabard B, Walser RJJ. Note on the metabolism of the mercury chelating agent sodium 2,3-dimercaptopropane-1-sulfonate. Toxicol Environ Health, 1979 Jul;5(4):759-64.


866 Gonzalez-Ramirez D, et al. DMPS (2,3-dimercaptopropane-1-sulfonate, dimaval) decreases the body burden of mercury in humans exposed to mercurous chloride. J Pharmacol Exp Ther, 1998 Oct;287(1):8-12.


867 Aposhian HV. Mobilization of Mercury and Arsenic in Humans by Sodium 2,3-Dimercapto-1-propane Sulfonate (DMPS). J Environ Health Perspect, 1998;106(4):1017-1025.


868 Personal communication, Dr E Blaurock-Busch PhD, Micro Trace Minerals Laboratory Services. www.microtrace.de.


869 Hurlbut KM, et al. Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther, 1994 Feb;268(2):662-8.


870 Maiorino RM, Aposhian HV. Determination and metabolism of dithiol chelating agents. IV. Urinary excretion of meso-2,3-dimercaptosuccinic acid and mercaptosuccinic acid in rabbits given meso-2,3-dimercaptosuccinic acid. Biochem Pharmacol, 1989;38:1147-1154.


871 Waelti S. Pharmakokinetik der uroprotektiven Sulfhydrylgruppen in Urin gesunder Probanden nach

peroraler Verabreichung von Na-mercaptoethansulfonat und von Na-Dimercaptopropansulfonat

(Dimaval) (dissertation). Bern, 1992.


872 Vamnes JS, et al. Diagnostic value of a chelation agent in patients with symptoms allegedly caused by amalgam fillings. J Dent Res, 2000;79(3):868-874.


873 Schiele R, Kroncke A. Mercury mobility through DMPS (Dimaval) in persons with and without amalgam fillings. Zahndrztl Mitt, 1989;79:1866-8.


874 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J Pharmacol Exp Ther, 1996 Apr;277(1):375-84.


875 Wildenauer DB, et al. Interactions of the chelating agent 2,3-dimercaptopropane-1-sulfonate with

red blood cells in vitro. I. Evidence for carrier mediated transport. B1379 1982 Nov;42(2):165-77.


876 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents. III. Formation of oxidized metabolites of 2,3-dimercaptopropane-1-sulfonic acid in rabbit. Drug Metab Dispos, 1988 May-Jun;16(3):455-63.


877 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents. III. Formation of oxidized metabolites of 2,3-dimercaptopropane-1-sulfonic acid in rabbit. Drug Metab Dispos, 1988 May-Jun;16(3):455-63.


878 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents. III. Formation of oxidized metabolites of 2,3-dimercaptopropane-1-sulfonic acid in rabbit. Drug Metab Dispos, 1988 May-Jun;16(3):455-63.


879 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J Pharmacol Exp Ther, 1996 Apr;277(1):375-84.


880 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J Pharmacol Exp Ther, 1996 Apr;277(1):375-84.


881 Hurlbut KM, et al. Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther, 1994 Feb;268(2):662-8.


882 Schiele R, Kroncke A. Mercury mobility through DMPS (Dimaval) in persons with and without amalgam fillings. Zahndrztl Mitt, 1989;79:1866-1868.


883 Herrmann M, Schweinsberg F. Biomonitoring zur Beurteilung einer Quecksilberbelastung aus Amalgamfullungen. Quecksilberbestimmung in Urin vor und nach oraler Gabe von 2,3-Dimaercapto- I -Propansulfonsatire (DMPS) und in Haaren. Zentralbl Hvg Umweltmed, 1993;194:271-291.


884 Cherian MG, et al. Estimation of mercury burdens in rats by chelation with dimercaptopropane sulfonate. J Pharmacol Exp Ther, 1988; 245:479-484.


885 Ewan KB, Pamphlett R. Increased inorganic mercury in spinal motor neurons following chelating agents. Neurotoxicology, 1996, 17:343-349.


886 Aposhian MM, et al. Sodium 2,3-dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rat. Toxicology, 1996;109:49-55.


887 Maiorino RM, Aposhian HV. Determination and metabolism of dithiol chelating agents. IV. Urinary excretion of meso-2,3-dimercaptosuccinic acid and mercaptosuccinic acid in rabbits given meso-2,3-dimercaptosuccinic acid. Biochem Pharmacol, 1989;38:1147-1154.


888 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J Pharmacol Exp Ther, 1991;259:808-14.


889 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J Pharmacol Exp Ther, 1991;259:808-14.


890 Maiorino RM, et al. Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. III. Urinary mercury after exposure to mercurous chloride. J Pharmacol Exp Ther, 1996;277(2):938-44.


891 Nerudová J, et al. Mobilization of mercury by DMPS in occupationally exposed workers and in model experiments on rats: evaluation of body burden. Int J Occup Med Environ Health, 2000;13(2):131-46.


892 Molin M, et al. Mobilized mercury in subjects with varying exposure to elemental mercury vapour. Int Arch Occup Environ Health, 1991;63(3):187-92.


893 Aaseth J, et al. Treatment of mercury and lead poisonings with dimercaptosuccinic acid and sodium dimercaptopropanesulfonate. A review. Analyst, 1995,120:853-854.


894 Gonzalez-Ramirez D, et al. DMPS (2,3-Dimercaptopropane-1-sulfonate, Dimaval) decreases the body burden of mercury in humans exposed to mercurous chloride. J Pharmacol Exp Ther, 1998 Oct;287(1):8-12.


895 Aposhian HV, et al. Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid: correlation with dental amalgam score. FASEB J, 1992 Apr;6(7):2472-6.


896 Vamnes JS, et al. Diagnostic value of a chelating agent in patients with symptoms allegedly caused by amalgam fillings. Dent Res, 2000 Mar;79(3):868-74.


897 Zander D, et al. The mercury exposure of the population. III. Mercury mobilisation by DMPS (Dimaval) in subjects with and without amalgam fillings. Zentralbl Hyg Umweltmed, 1992 Feb;192(5):447-54.


898 Sandborgh Englund G, et al. DMSA administration to patients with alleged mercury poisoning from dental amalgams: a placebo-controlled study. J Dent Res, 1994 Mar; 73(3):620-8.


899 Brandão R, et al.Antioxidants and metallothionein levels in mercury-treated mice. Cell Biol Toxicol, 2006 Nov;22(6):429-38.


900 Suzuki S, et al. Protective effects of 2,3-dimercaptopropane-1-sulfonate on mercuric chloride-induced acute inhibition of enzymes from rat duodenal mucosa and kidney cortex. Toxicology, 1994 Jan 26;86(1-2):29-48.


901 Paranandi N. Enhancement of regenerative capacity of cells is critical for healing of tissue that encounters heavy metal toxicity. IAOMT (SA) 2009 Integrated dental and medical health care conference, Cape Town, 15 – 17 May 2009.


902 George GN, et al. Mercury binding to the chelation therapy agentsDMSAandDMPSand the rational design of custom chelators for mercury. Chem Res Toxicol, 2004;17:999–1006.


903 Buchet JP, Lauwerys RR. Influence of 2,3-dimercaptopropane-1-sulfonate and dimercaptosuccinic acid on the mobilization of mercury from tissues of rats pretreated with mercuric chloride, phenylmercury acetate or mercury vapors. Toxicology, 1989;54, 323–333.


904 Aposhian HV, et al. Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to Hg vapor. J Toxicol Clin Toxicol, 2003;41:339–347.


905 Aaseth J, Frieheim EA.Treatment of methyl mercury poisoning in mice with 2,3-dimercaptosuccinic acid and other complexing thiols. Acta Pharmacol Toxicol (Copenh), 1978 Apr;42(4):248-52.


906 Aaseth J, Frieheim EA.Treatment of methyl mercury poisoning in mice with 2,3-dimercaptosuccinic acid and other complexing thiols. Acta Pharmacol Toxicol (Copenh), 1978 Apr;42(4):248-52.


907 Aaseth J, et al. Treatment of mercury and lead poisonings with dimercaptosuccinic acid and sodium dimercaptopropanesulfonate. A review. Analyst,1995 Mar;120(3):853-4.


908 Kostyniak PJ. Methylmercury removal in the dog during infusion of 2,3-dimercaptosuccinic acid (DMSA). J Toxicol Environ Health, 1983 Apr-Jun;11(4-6):947-57.


909 Ewan KB, Pamphlett R. Increased inorganic mercury in spinal motor neurons following chelating agents. Neurotoxicology,1996 Summer;17(2):343-9.


910 Rooney JPK. The role of thiols, dithiols, nutritional factors and interacting ligands in the toxicology of Hg. Toxicology 234, 2007:145–156.


911 Van Der Schaar PJ. Clinical Metal Toxicology. IBCMT 5th ed. Holland. 2006.


912 Planas-Bohne F.The influence of chelating agents on the distribution and biotransformation of methylmercuric chloride in rats. J Pharmacol Exp Ther,1981 May;217(2):500-4.


913 Maiorino RM, et al. Determination and metabolism of dithiol chelating agents: X. In humans,

meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation.

J Pharmacol Exp Ther,1990 Aug;254(2):570-7.


914 Frumkin H, et al. Diagnostic chelation challenge with DMSA: a biomarker of long-term

mercury exposure? Environ Health Perspect, 2001:109: 167-71.


915 Aposhian HV, et al. Mobilization of heavy metals by newer, therapeutically useful chelating

agents. Toxicology, 1995;97:23-38.


916 Rooney JPK. The role of thiols, dithiols, nutritional factors and interacting ligands in the toxicology

of mercury. Toxicology, 2007;234:145-56.


917 Aposhian HV, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology, 1995;97:23-38.


918 Clarkson TW. The pharmacology of mercury compounds. Ann Rev Pharmacol, 1972;12:375-406.


919 Zheng W, et al Determination and metabolism of dithiol chelating agents. VII. Biliary excretion of dithiols and their interactions with cadmium and metallothionein. B1446, 1990 Apr;14(3):598-607.


920 Miller AL. Dimercaptosuccinic acid (DMSA), a non-toxic, water-soluble treatment for heavy metal toxicity. Altern Med Rev, 1998 Jun;3(3):199-207.


921 Fournier L, et al. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp, 1988 Nov-Dec;3(6):499-504.


922 Fayez I, et al. Toxicokinetics of mercury elimination by succimer in twin toddlers. Paediatr Drugs, 2005;7(6):397-400.


923 Torres-Alanís O, et al. Evaluation of urinary mercury excretion after administration of 2,3-dimercapto-1-propane sulfonic acid to occupationally exposed men. J Toxicol Clin Toxicol, 1995;33(6):717-20.


924 Forman J, et al. A cluster of pediatric metallic mercury exposure cases treated with meso-2,3-dimercaptosuccinic acid (DMSA). Environ Health Perspect., 2000 Jun; 108(6):575-7.


925 Matts RL, et al. Toxic heavy metal ions activate the heme-regulated eukaryotic initiation factor-2 alpha kinase by inhibiting the capacity of hemin-supplemented reticulocyte lysates to reduce disulfide bonds. J Biol Chem, 1991 Jul 5;266(19):12695-702


926 Tandon SK, Magos L. Effect of kidney damage on the mobilisation of mercury by thiol-complexing agents. Br J Ind Med, 1980 May;37(2):128-32.


927 Planas-Bohne F, et al. Toxicological studies on sodium 2,3-dimercaptopropane-1-sulfonate in the rat. Arzneimittelforschung, 1980;30(8):1291-4.


928 Sanchez DJ, et al. Effects of meso-2,3-dimercaptosuccinic acid (DMSA) on methyl mercury-induced teratogenesis in mice. Ecotoxicol Environ Saf, 1993 Aug;26(1):33-9.


929 Liang YY, et al. Disposition of [14C] dimercaptosuccinic acid in mice. Fundam Appl Toxicol, 1986 Apr; 6(3):532-40.


930 Karunasagar D, et al. Removal and preconcentration of inorganic and methyl mercury from aqueous media using a sorbent prepared from the plant Coriandrum sativum. J Hazard Mater, 2005 Feb 14;118(1-3):133-9.


931 Omura Y, et al. Significant mercury deposits in internal organs following the removal of dental amalgam, & development of pre-cancer on the gingiva and the sides of the tongue

and their represented organs as a result of inadvertent exposure to strong curing light (used to solidify synthetic dental filling material) & effective treatment: a clinical case

report, along with organ representation areas for each tooth. B14691996 Apr-Jun;21(2):133-60.


932 Omura Y, Beckman SL. Role of mercury (Hg) in resistant infections & effective treatment of Chlamydia trachomatis and Herpes family viral infections (and potential

treatment for cancer) by removing localized Hg deposits with Chinese parsley and delivering effective antibiotics using various drug uptake enhancement methods.

Acupunct Electrother Res, 1995 Aug-Dec;20(3-4):195-229.


933 Cain A, et al. Cyanobacteria as a biosorbent for mercuric ion. Bioresour Technolhr. 2008 Sep;99(14):6578-86.


934 Sharma MK, et al. Evaluation of protective efficacy of Spirulina fusiformis against mercury induced nephrotoxicity in Swiss albino mice. Food and Chemical Toxicology, 2007;45:879-87.


935 Sharma MK, et al. Evaluation of protective efficacy of Spirulina fusiformis against mercury induced nephrotoxicity in Swiss albino mice. Food and Chemical Toxicology, 2007;45:879-87.


936 Yardim MF. Removal of mercury (II) from aqueous solution by activated carbon obtained from furfural. Chemosphere, 2003; 52: 835-41.


937 Jürgens G, et al. The effect of activated charcoal on drug exposure in healthy volunteers: a meta-analysis. Clin Pharmacol Ther, 2009 May;85(5):501-5.


938 VanderSchaar PJ. Clinical Metal Toxicology. 2006 Ed. Available from This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


939 Matts RL, et al. Toxic heavy metal ions activate the heme-regulated eukaryotic initiation factor-2 alpha kinase by inhibiting the capacity of hemin-supplemented reticulocyte lysates to reduce disulfide bonds. B14281991 Jul 5;266(19):12695-702


940 VanderSchaar PJ. Clinical Metal Toxicology. 2006 Ed. Available from This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


941 Ou S, et al. An in vitro study of wheat bran bindingcapacity for Hg, Cd and Pb. J. Agric. Food Chem, 1999;47:4714-7.


942 Rowland IR, et al. The effect of various dietary fibres on tissue concentration and chemical form of mercury after methylmercury exposure in mice. Arch Toxicol, 1986;59:94-8.


943 Sobolev MB, et al.. Enterosorption by nonstarch polysaccharides as a method of treatment of children with mercury poisoning. Vopr Pitan, 1999;68:28–30.


944 Hckey S, Roberts H. Ascorbate. The science of Vitamin C. 2004. ISBN 1-4116-0724-4


945 Divine KK, et al. Glutathione, albumin, cysteine and cys-gly effects on toxicity and accumulation of mercuric chloride in LLC-PK1 cells. J Toxicol Environ Health A, 1999;57:489-505.


946 Sen C. Nutritional biochemistry of cellular glutathione. J Nutr Biochem, 1997;8:660-72.


947 Lee YW, et al. Role of reactive oxygen species and glutathione in inorganic mercury-induced injury in human glioma cells. Neurochem Res, 2001;26:1187-93.


948 Queiroz ML, et al. Abnormal antioxidant system in erythrocytes of mercury-exposed workers. Hum Exp Toxicol, 1998;17:225-30.


949 Zalups RK. Molecular interactions with mercury in the kidney. Pharmacol Rev, 2000;52:113-43.


950 Lee YW, et al. Role of reactive oxygen species and glutathione in inorganic mercury-induced injury in human glioma cells. Neurochem Res, 2001;26:1187-93.


951 Packer L, et al. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition, 2001;17:888-95.


952 Zalups RK. Molecular interactions with mercury in the kidney. Pharmacol Rev, 2000;52:113-43.


953 Ballatori N, Clarkson TW. Dependence of biliary secretion of inorganic mercury on the biliary transport of glutathione. Biochem Pharmacol, 1984;33:1093-98.


954 Kromidas L, et al. The protective effects of glutathione against methylmercury cytotoxicity. Toxicol Lett, 1990;51:67-80.


955 Ballatori N, Clarkson TW. Biliary transport of glutathione and methylmercury. Am J Physiol, 1983;244:G435-G441.


956 Alexander J, Aaseth J. Organ distribution and cellular uptake of methyl mercury in the rat as influenced by the intra- and extracellular glutathione concentration. Biochem Pharmacol, 1982;31:685-90.


957 Magos L, et al. The interrelationship between non-protein bound thiols and the biliary excretion of methylmercury. Biochem Pharmacol, 1978;27:2203-8.


958 Gregus Z, Varga F. Role of glutathione and hepatic glutathione S-transferase in the biliary excretion of methyl mercury, cadmium and zinc: a study with enzyme inducers and glutathione depletors. Acta Pharmacol Toxicol (Copenh), 1985;56:398-403.


959 Gregus Z, Varga F. Role of glutathione and hepatic glutathione S-transferase in the biliary excretion of methyl mercury, cadmium and zinc: a study with enzyme inducers and glutathione depletors. Acta Pharmacol Toxicol (Copenh), 1985;56:398-403.


960 Endo T, Sakata M. Effects of sulfhydryl compounds on the accumulation, removal and cytotoxicity of inorganic mercury by primary cultures of rat renal cortical epithelial cells. Pharmacol Toxicol, 1995;76:190-5.


961 Bridges CC, Zalups RK. Molecular and ionic mimicry and the transport of toxic metals. Toxicol. Appl Pharmacol, 2005;204:274-308.


962 Kerper LE, et al. Methylmercury efflux from brain capillary endothelial cells is modulated by intracellular glutathione but not ATP. Toxicol Appl Pharmacol, 1996;141:526


963 Cookson MR, Pentreath VW. Protective roles of glutathione in the toxicity of mercury and cadmium compounds to C6 glioma cells. Toxicol In Vitro, 1996;10:257-64.


964 Tiffany-Castiglion E, Qian Y. Astroglia as metal depots: molecular mechanisms for metal accumulation, storage and release. Neurotoxicology, 2001;22:577-92.


965 Packer L, et al. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med, 1995;19:227-50.


966 Packer L, et al. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med, 1997;22:359-78.


967 Grunert RR. The effect of dl-alpha-lipoic acid on heavymetal intoxication in mice and dogs. Arch Biochem Biophys, 1960;86:190-94.


968 Aposhian HV, et al. Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to mercury vapour. J Toxicol Clin Toxicol, 2003;41:339-47.


969 Gregus Z, et al. Effect of lipoic acid on biliary excretion of glutathione and metals. Toxicol Appl Pharmacol, 1992 May;114(1):88-96.


970 Gregus Z, et al. Effect of lipoic acid on biliary excretion of glutathione and metals. Toxicol Appl Pharmacol, 1992 May;114(1):88-96.


971 Boudou A, Ribeyre F. Comparative study of the trophic transfer of two mercury compounds-HgCl2 and CH3HgCl-between Chlorella vulgaris an Daphnia magna. Influence of temperature.Bull Environ Contam Toxicol, 1981 Nov;27(5):624-9


972 VanderSchaar PJ. Clinical Metal Toxicology. 2006 Ed. Available from This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


973 VanderSchaar PJ. Clinical Metal Toxicology. 2006 Ed. Available from This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


974 Aposhian HV, et al. Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to mercury vapour. J Toxicol Clin Toxicol, 2003;41:339-47.


975 Zalups RK, Ahmad S. Transport of N-acetylcysteine S-conjugates of methylmercury in Madin-Darby canine kidney cells stably transfected with human isoform of organic anion transporter 1. J Pharmacol Exp Ther, 2005;314:1158-68.


976 Brandão R, et al. Antioxidants and metallothionein levels in mercury-treated mice. Cell Biol Toxicol, 2006 Nov;22(6):429-38.


977 VanderSchaar PJ. Clinical Metal Toxicology. 2006 Ed. Available from This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


978 Goyer R, et al. Metal Toxicology. Academic Press, 1995:35-7.


979 Yamamoto I. Effect of various amounts of selenium on the metabolism of mercuric chloride in mice. Biochem Pharmacol, 1985;34:2713-20.


980 Gailer J, et al. Structural basis of the antagonism between inorganic mercury and selenium in mammals. Chem Res Toxico, 2000;13:1135-42.


981 Sasakura C, Suzuki KT. Biological interaction between transition metals (Ag, Cd and Hg), selenide/sulfide and selenoprotein P. J Inorg Biochem, 1998;71:159-62.


982 Hol PJ, et al. Dental amalgam and selenium in blood. Environ. Res, 2001;87:141-6.


983 Hill KE, Burk RF. Effect of selenium deficiency on the disposition of plasma glutathione. Arch Biochem Biophys, 1985;240:166-71.


984 VanderSchaar PJ. Clinical Metal Toxicology. 2006 Ed. Available from This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


985 Oke AF et al. Ascorbic acid distribution patterns in human brain. A comparison with nonhuman mammalian species. Paper presented at the Third New York Academy of Sciences Conference on Vitamin C. 8-10 October 1987, New York City.


986 Oke AF et al. Ascorbic acid distribution patterns in human brain. A comparison with nonhuman mammalian species. Paper presented at the Third New York Academy of Sciences Conference on Vitamin C. 8-10 October 1987, New York City.


987 Cheraskin E, et al. The vitamin C connection. Harper and Rown, Inc. 1983, ISBN 0-553-24434-5. p 13.


988 Klenner F. Observations on the dose and administration of ascorbic acid when employed beyond the range of a vitamin in human pathology. J Appl Nutrition, 1971;23(3&4):61-88.


989 Cathcart RF. Vitamin C: the non-toxic, nonrate-limited, antioxidant free radical scavenger. Medical Hypothesis, 1985;18:61-77.


990 Hickey S, Roberts H. Ascorbate. The science of Vitamin C. ISBN 1-4116-0724-4.


991 Douglas RM, et al. Vitamin C for preventing and treating the common cold (Cochrane Review) 2001. IN: The Cochrane Library 3, Oxford: update software, CD 000980.


992 Hickey S, Roberts H. Ascorbate. The science of Vitamin C. ISBN 1-4116-0724-4.


993 Hickey S, Roberts H. Ascorbate. The science of Vitamin C. ISBN 1-4116-0724-4.


994 Garry PJ, et al. Ascorbic acid intake and plasma levels in healthy elderly. Paper presented at the Third New York Academy of Sciences Conference on Vitamin C. 8-10 October 1987, New York City.


995 Food and Nuitrition Board. RDA, 1979-1980.


996 Stähelin HB, et al. Plasma vitaminc C and cancer death: the prospective basel study. Paper presented at the Third New York Academy of Sciences Conference on Vitamin C. 8-10 October 1987, New York City.


997 Kallner A, et al. On the absorption of ascorbis acind in man. Int J Vitamin and Nutrition Res, 1977;47:383-8.


998 Hickey S, Roberts H. Ascorbate. The science of Vitamin C. ISBN 1-4116-0724-4.


999 Curhan GC, et al. Megadose vitamin C consumption does not cause kidneys tones. Intake of Vitmains B6 and C and the rik of kidney stones in women. J Am Soc Nephrol, 1996;10(4):840-845. (85 557 women were evaluated for 14 years.)


1000 Curhan GC, et al. A prospective study of the intake of vitamins B6 and C and the risk of kidney stones in men. J Urol, 1996;155(6):1847-1851. (45,251 men were studied).


1001 McCormick WJ. Ascorbic acid as a chemotherapeutic agent. Arch of Pediatrics, 1952;69(4): 151-5.


1002 Rawal BD, et al. Inhibition of Pseudomonas Aeruginosa by ascorbic acid acting singly and in combination with antimicrobials: in-vitro and in-vivo studies. Medical J Australia, 1974;1(6):169-74.


1003 Aposhian HV, et al. Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to mercury vapor. J Toxicol Clin Toxicol, 2003;41(4):339-47.


1004 Calabrese EJ, et al. The effects of vitamin C supplementation on blood and hair levels of cadmium, lead and mercury. Ann N Y Acad Sci, 1987;498:347-53.


1005 Dirks MJ, et al. Mercury excretion and intravenous ascorbic acid. Arch Environ Health, 1994 Jan-Feb;49(1):49-52.


1006 Hill CH. Interactions of vitamin C with lead and mercury. Ann NY Acad Sci, 1979;355:262-5.


1007 Chatterjee GC, Pal DR. Metabolism of L-ascorbic acid in rats under in vivo administration of mercury: effect of l-ascorbic acid supplementation. Int J Vitam Nutr Res, 1975;45:284-292.


1008 Chatterjee GC, Pal DR. Metabolism of L-ascorbic acid in rats under in vivo administration of mercury: effect of l-ascorbic acid supplementation. Int J Vitam Nutr Res, 1975;45:284-292.


1009 Haley, B. www.iaomt.org


1010 Hickey S, Roberts H. Ascorbate. The science of Vitamin C. ISBN 1-4116-0724-4.


1011 Cheraskin E, et al. The vitamin C connection. Harper and Rown, Inc. 1983, ISBN 0-553-24434-5. p 13.


1012 http://www.livonlabs.com/


1013 Huggins, HA. Protocol for amalgam removal and dental revision. Available from www.hugnet.com.


1014 Rhee P, et al. QuikClot use in trauma for hemorrhage control: case series of 103 documented uses. J Trauma April 2008;64(4):1093-9.


1015 Auerbach KA, et al. Handbook of zeolite science and technology. Dutta, eds. CRC Press, 2003.


1016 Papaioannoua D, et al. The role of natural and synthetic zeolites as feed additives on the prevention and/or the treatment of certain farm animal diseases: A review. Microporous and Mesoporous Materials, September 2005;84(1-3, 15):161-170.


1017 Omura Y, Beckman SL. Role of mercury (Hg) in resistant infections & effective treatment of Chlamydia trachomatis and Herpes family viral infections (and potential treatment for cancer) by removing localized Hg deposits with Chinese parsley and delivering effective antibiotics using various drug uptake enhancement methods. Acupunct Electrother Res, 1995 Aug-Dec;20(3-4):195-229.


1018 Cranmer M, et al. Neurotoxicity of mercury-indicators and effects of low-level exposure: overview. Neurotoxicology 1996;17(1):9–14.


1019 Barregård L, et al. Kvikksølveksponering fra amalgam. Tidsskr Nor Lægeforen, 1998; 118:58–62.


1020 Barregård L, et al. People with high mercury uptake from their own dental amalgam fillings. Occup Environ Med, 1995; 52(2):124–128.


1021 Ahlqwist M, et al. Serum mercury concentration in relation to survival, symptoms and diseases: results from the prospective population study of women in Gothenburg, Sweden. Acta Odontol Scand, 1999; 57(3):168–174.


1022 Ahlqwist M, et al. Number of amalgam tooth fillings in relation to subjectively experienced symptoms in a study of Swedish women. Community Dentistry & Oral Epidemiology, 1988;16(4):227–31.


1023 Ahlqwist M, et al. Number of amalgam fillings in relation to cardiovascular disease, diabetes, cancer and early death in Swedish women. Community Dentistry & Oral Epidemiology, 1993; 21(1):40–44.


1024 Bengtsson C, et al. Inget samband mellan antal amalgamfyllningar och hälsa. Epidemiologiska erfarenheter från populationsstudie av kvinnor i Göteborg. Läkartidningen, 2001; 98(9):930-3.


1025 Best management practices for amalgam waste. October 2007. Www.ada.org. Accessed March 2009.


1026 ADA guidelines on amalgam accumulations in dental office: http://www.ada.org/prof/resources/positions/statements/amalgam_plumbing_guidelines.pdfm. Accessed July 2009.


1027 Best management practices for amalgam waste. October 2007. Www.ada.org. Accessed March 2009.


1028 Gioda A, et al. A pilot study to determine mercury exposure through vapor and bound to PM10 in a dental school environment. Toxicol Ind Health, 2007; 23; 103-13.


1029 Omura Y, et al. Significant mercury deposits in internal organs following the removal of dental amalgam, & development of pre-cancer on the gingiva and the sides of the tongue and their represented organs as a result of inadvertent exposure to strong curing light (used to solidify synthetic dental filling material) & effective treatment: a clinical case report, along with organ representation areas for each tooth. Acupunct Electrother Res, 1996 Apr-Jun;21(2):133-60.


1030 Sandborgh-Englund G, et al. Mercury in biological fluids after amalgam removal. J Dent Res, 77(4): 615-624, April, 1998.


1031 Begerow J, et al. Long-term mercury excretion in urine after removal of amalgam fillings. Int Arch Occup Health, 1994;66:209-12.


1032 Molin M, et al. Mercury, selenium and GPX before and after amalgam removal. Acta Odontol Scand, 1990;48:189-202.


1033 Molin M, et al. Mercury, selenium and GPX before and after amalgam removal. Acta Odontol Scand, 1990;48:189-202.


1034 Z?otkowska R, Zajac-Nedza M. Occupational acute mercury intoxication--a case report. Med Pr, 2002;53(4):315-7.


1035 Koizumi A, et al. Mercury, not sulphur dioxide, poisoning as cause of smelter disease in industrial plants producing sulphuric acid. Lancet, 1994 Jun 4;343(8910):1411-2.


1036 Ferracane JL, et al. Reduction in operatory mercury levels after contamination or amalgam removal. Am J Dent, 1994 Apr;7(2):103-7.


1037 Berglund A, Molin M. Mercury levels in plasma and urine after removal of all amalgam restorations: the effect of using rubber dams. J Dent Mater,1997; 13 (5): 297-304.


1038 Kremers L, et al. Effect of rubber dam on mercury exposure during amalgam removal. Eur J Oral Sci, 1999;107(3):202-7.


1039 http://www.uib.no/bivirkningsgruppen/BVGtxt/am_rem_english.htm.


1040 Kremers L, et al. Effect of rubber dam on mercury exposure during amalgam removal. Eur J Oral Sci, 1999;107(3):202-7.


1041 Sandborgh-Englund G, et al. Mercury in biological fluids after amalgam removal. J Dent Res, 1998 77(4): 615-24.


1042 Huggins HA. Protocol for amalgam removal and dental revision. Available from www.hugnet.com.


1043 Huggins HA. Protocol for amalgam removal and dental revision. Available from www.hugnet.com.


1044 Huggins HA. It's all in your head. Available from www.hugnet.com.


1045 Sandborgh-Englund G, et al. Mercury in biological fluids after amalgam removal. J Dent Res, 1998 77(4): 615-24.


1046 Pohl L, Bergman M. The dentist's exposure to elemental mercury vapor during clinical work with amalgam. Acta Odontol Scand, 1995 Feb;53(1):44-8.


1047 Yardim MF, et al. Removal of mercury (II) from aqueous solution by activated carbon obtained from furfural. Chemosphere, 2003 Aug;52(5):835-41.


1048 Ly BT, et al. Mercuric oxide poisoning treated with whole-bowel irrigation and chelation therapy. Ann Emerg Med, 2002 Mar;39(3):312-5.


1049 Huggins HA, Levy TE. Cerebrospinal fluid protein changes in multiple sclerosis after dental amalgam removal. Altern Med Rev, 1998;3(4):295-300.


1050 Price W. Dental Infections Oral and Systemic. Cleveland, OH. Penton Publishing Company, 1923; & Price W. Dental Infections and the Degenerative Diseases. Cleveland, OH. Penton Publishing Company, 1923.


1051 Huggins HA. Protocol for amalgam removal and dental revision. Available from www.hugnet.com.


1052 Domestic Policy Subcommittee, Oversight and Government Reform Committee Tuesday, July 8, 2008. www.domesticpolicy.oversight.house.gov/documents/20080709102948.pdf.


1053 Vandeven J McGinnis SL. An assessment of mercury in the form of amalgam in dental wastewater in the United States Water. Air and Soil Pollution, 2005;164:349-66.


1054 Kennedy CJ. Uptake and accumulation of mercury from dental Amalgam in the common goldfish, Carassius auratus. Environ Pollut, 2003;121(3):321-6.


1055 Stone ME, et al. Residual mercury content and leaching of mercury and silver from used amalgam capsules. Dent Mater, 2002 Jun;18(4):289-94.


1056 Roberts HW, et al. Disinfectants' effect on mercury release from amalgam. JADA, 2005 Jul;136(7):915-9.


1057 Koizumi A, et al. Mercury, not sulphur dioxide, poisoning as cause of smelter disease in industrial plants producing sulphuric acid. Lancet, 1994 Jun 4;343(8910):1411-2.


1058 Ritchie KA. Mercury vapour levels in dental practices and body mercury levels of dentists and controls. Br Dent J, 2004 Nov 27;197(10):625-32.


1059 EPA Notice of Final 2008 Effluent Guidelines Program Plan, 73 Fed. Reg. 53,219, 53,234 (September 15, 2008) (EPA Final 2008 Effluent Guidelines Plan FR Notice).


1060 Testimony of Mr. Ephraim King, Director, Office of Science and Technology, Office of Water, EPA before the Domestic Policy Subcommittee of the Oversight and

Government Reform Committee on Environmental Risks Of And Regulatory Response To Mercury Dental Fillings. November 14, 2007, Rayburn, Washington, D.C.

www.domesticpolicy.oversight.house.gov/documents/20071115094710.pdf


1061 EPA Notice of Final 2008 Effluent Guidelines Program Plan, 73 Fed. Reg. 53,219, 53,234 (September 15, 2008) (EPA Final 2008 Effluent Guidelines Plan FR Notice).


1062 Domestic Policy Subcommittee, Oversight and Government Reform Committee at its hearing on Assessing State and Local Regulations to Reduce Dental Mercury Emissions, Tuesday, July 8, 2008. www.domesticpolicy.oversight.house.gov/documents/20080709103529.pdf.


1063 Langan DC, et al. The use of Mercury in dentistry: a critical review of the literature. JADA, December 1987;115:867-80.


1064 Lindvall A, et al. Mercury in the dental practice: contamination of ambient air and waste water, FDI World Dental Congress, 19 Aug 1993, Goteborg,Sweden.


1065 Rubin PG, Yu M-H. Mercury vapor in amalgam waste discharged from dental office vacuum units. Arch Environ Health, Jul 1996;51(4):335-7.


1066 Larsen AH, et al. Mercury discharge in waste water from dental clinics. Water Air and Soil Pollution, Jan 1996;86(1-4):93-9.


1067 Jones DW. Putting dental mercury pollution into perspective. Br Dent J, 2004 Aug 28;197(4):175-7.


1068 Jones DW. Putting dental mercury pollution into perspective. Br Dent J, 2004 Aug 28;197(4):175-7.
1069 Anderson K. Creating an environmentally friendly dental practice. CDS Rev 1999:12-8.


1070 Chin G, et al. The environmental effects of dental amalgam. Aust Dent J, 2000; 45(4):246–9.


1071 Adegbembo AO, Watson PA. Estimated quantity of mercury in amalgam waste water residue released by dentists into the sewerage system in Ontario, Canada. J Can Dent Assoc, 2004;70(11):759a–f.


1072 Domestic Policy Subcommittee, Oversight and Government Reform Committee Tuesday, July 8, 2008, 2154 Rayburn, HOB. www.domesticpolicy.oversight.house.gov/documents/20080709102948.pdf.

1073 Testimony of Dr Richard Fisher on behalf of the IAOMT before the Domestic Policy Subcommittee,

Oversight and Government Reform Committee on Assessing State and Local Regulations to

Reduce Dental Mercury Emissions. ttp://domesticpolicy.oversight.house.gov/documents/20080709103529.pdf.


1074 www.flcv.com/damspr2f.html.


1075 Brodsky JB. Occupational exposure to mercury in dentistry and pregnancy outcome. JADA, 19

85;111(11):779-80.


1076 Kuntz WD. Maternal and chord blood mercury background levels: longitudinal surveilance.

Am J Obstet Gynecol, 1982;143(4):440-3.


1077 Kuhnert P, et al. Comparison of Mercury levels in maternal blood fetal cord blood and placental

tissue. Am J Obstet Gynecol, 1982;139:209-12.


1078 Testimony of Patricia Magnuson, King County, Washington, before the U.S. House of

Representatives, Domestic Policy Subcommittee of the Oversight and Government Reform

Committee, at its hearing on Assessing State and Local Regulations to Reduce Dental Mercury

Emissions, held July 8, 2008. www.domesticpolicy.oversight.house.gov/documents/20080709104012.pdf.


1079 Testimony of Norris Alders, Ph.D., Director, Office of Science and Health, FDA, U.S. Department

of Health and Human Services before the Committee on Oversight and Government Reform

Subcommittee, Domestic Policy, House of Representatives on Environmental Risks Of And

Regulatory Response To Mercury Dental Fillings regarding the FDA’s implementation of the

National Environmental Policy Act of 1969. 14 November 2007.

http://domesticpolicy.oversight.house.gov/documents/20071115095440.pdf.


1080 Cain A. Mercury Flow Workbook, US EPA, Region 5, January 2006.


1081 Testimony of Dr Richard Fisher on behalf of the IAOMT before the Domestic Policy Subcommittee,

Oversight and Government Reform Committee on Assessing State and Local Regulations to Reduce

Dental Mercury Emissions. http://domesticpolicy.oversight.house.gov/documents/20080709103529.pdf.


1082 Skare I, Engqvist A. Human exposure to mercury and silver released from dental amalgam

restorations. Arch Env Health, 1994 Sep-Oct;49(5):384-94.


1083 Skare I, Engqvist A. Amalgam restorations - an important source of human exposure of mercury

and silver. Lakartidningen, 1992;15:1299-301.


1084 Aposhian HV, et al. Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid:

correclation with amalgam score. FASEB J, April 1992;6:2472-6.


1085 Testimony of Ann Farrell, Director of Engineering, Central Contra Costa Sanitary District, Marinez,

California before the subcommittee on Domestic Policy of the Committee on Oversight and

Government Reform, U.S. House of Representatives at its hearing on Assessing State and Local

Regulations to Reduce Dental Mercury Emissions, July 8, 2008.

www.domesticpolicy.oversight.house.gov/documents/20080709104048.pdf.


1086 Leistevuo J, et al. Mercury in saliva and the risk of exceeding limits for sewage in relation to

exposure to amalgam fillings. Arch Environ Health, 2002 Jul-Aug; 57(4):366-70.


1087 Guidelines for the Use of Dental Restorative Materials. Information to dental health personnel about

the use of dental materialsfor restoring single teeth. Issued by the Norwegian Directorate for Health

and Social Welfare, Norway issued 12/2003.

http://www.helsedirektoratet.no/vp/template/ver1-0/print.jsp?articleId=5695&sectionId=268 and

http://www.helsedirektoratet.no/vp/multimedia/archive/00001/A_National_Clinical_G_1661a.pdf

accessed 9 March 2009. Order reference: IS-1136.


1088 Guidelines for the Use of Dental Restorative Materials. Information to dental health personnel about

the use of dental materialsfor restoring single teeth. Issued by the Norwegian Directorate for Health

and Social Welfare, Norway issued 12/2003.

http://www.helsedirektoratet.no/vp/template/ver1-0/print.jsp?articleId=5695&sectionId=268 and

http://www.helsedirektoratet.no/vp/multimedia/archive/00001/A_National_Clinical_G_1661a.pdf

accessed 9 March 2009. Order reference: IS-1136.


1089 Testimony of Patricia Magnuson, King County, Washington, before the U.S. House of

Representatives, Domestic Policy Subcommittee of the Oversight and Government Reform

Committee, at its hearing on Assessing State and Local Regulations to Reduce Dental Mercury

Emissions, held July 8, 2008.

www.domesticpolicy.oversight.house.gov/documents/20080709104012.pdf.


1090 Testimony of Mr. Ephraim King, Director, Office of Science and Technology, Office of Water,

Environmental Protection Agency before the domestic policy subcommittee of the oeversight and

government reform committe on Environmental Risks Of And Regulatory Response To Mercury

Dental Fillings. November 14, 2007, Rayburn, Washington, D.C.

www.domesticpolicy.oversight.house.gov/documents/20071115094710.pdf.


1091 U.S. House of Representatives, Domestic Policy Subcommittee of the Oversight and Government

Reform Committee, at its hearing on Assessing State and Local Regulations to Reduce Dental

Mercury Emissions, Domestic Policy Subcommittee, Oversight and Government Reform Committee

Tuesday, July 8, 2008. www.domesticpolicy.oversight.house.gov/documents/20080709103627.pdf.


1092 Testimony of Curt McCormick, principle/owner, CWA Consulting Services, LLC. and Former

Administrator, EPA Region 8, Pretreatment Coordinator, before the U.S. House of Representatives,

Domestic Policy Subcommittee of the Oversight and Government Reform Committee, at its hearing

on Assessing State and Local Regulations to Reduce Dental Mercury Emissions, Domestic Policy

Subcommittee, Oversight and Government Reform Committee Tuesday, July 8, 2008.


1093 EPA, Notice of Final 2008 Effluent Guidelines Program Plan, 73 Fed. Reg. 53,219, 53,234.


1094 www.epa.gov/guide/dental.


1095 http://iaomt.org/news/archive.asp?intReleaseID=280&month=9&year=2008.


1096 Miljøverndepartementet. Handlingsplan for helse- og miljøfarlige kjemikalier. 1999.
1097 UNEP Chemicals. Global Mercury Assessment. 2002.


1098 Association of Metropolitan Sewerage Agencies (now the National Associantion of Clean Water

Agencies) . Mercury Source Control & Pollution Prevention Program Evaluation: Final Report.

March 2002 (Amended July 2002).


1099 http://domesticpolicy.oversight.house.gov/documents/20080709102948.pdf.


1100 Rubin PG, Yu M-H. Mercury vapor in amalgam waste discharged from dental office vacuum units.

Arch Env Health, Jul 1996;51(4):335-7.

1101 Philip L, Deshusses MA. The control of mercury vapor using biotrickling filters. Chemosphere,

2008 Jan;70(3):411-7.


1102 http://www.ada.org/prof/resources/topics/amalgam_bmp.asp accessed 21 May 2009.


1103 http://www.ada.org/prof/resources/topics/topics_amalgamwaste.pdf accessed 21 May 2009.


1104 Guidelines for the use of dental restorative materials. Information to dental health personnel about

the use of dental materials for restoring single teeth. Issued by the Norwegian Directorate for Health

and Social Welfare, Norway issued 12/2003.

http://www.helsedirektoratet.no/vp/template/ver1-0/print.jsp?articleId=5695&sectionId=268 and

http://www.helsedirektoratet.no/vp/multimedia/archive/00001/A_National_Clinical_G_1661a.pdf

accessed 9 March 2009. Order reference: IS-1136.


1105 http://www.ada.org/public/media/releases/0609_release01.asp. Accessed 15 March 2008.


1106 www.dentaleconomics.com. Accessed February 2008.


1107 Found on http://www.dentsply.com, but has subsequently been removed.


1108 http://www.msdsmarket.com.


1109 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm173992.htm.


1110 Class II Special Controls Guidance Document: Dental Amalgam, Mercury and Amalgam Alloy –

Guidance for Industry and FDA Staff, http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance

/GuidanceDocuments/ucm073311.htm (“The developing neurological systems in fetuses and

young children may be more sensitive to the neurotoxic effects of mercury vapor. Very limited to

no clinical information is available regarding long-term health outcomes in pregnant women and

their developing fetuses and children under the age of six, including infants who are breastfed.”)


1111 http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DentalProducts/Dental

Amalgam/ucm171094.htm.


1112 http://www.toxicteeth.org/Zogby%20Poll--Results%202006.pdf.


1113 High levels of mercury vapor exposure are associated with adverse effects in

the brain and the kidneys.

http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DentalProducts/DentalAmalgam

/ucm171094.htm.


1114 The Bank of America and J.P. Morgan reports predicting warnings for women and children.

www.toxicteeth.org/RB__565608.pdf and http://www.toxicteeth.org/JPMorgam-2008.pdf.


1115 Dickinson J. A ‘Shocking’ Decision – Bias Seen in Dental Amalgams Rule, FDA webview,

www.fdaweb.com, 31 July 2009 as discussed at http://www.toxicteeth.org/I_G_complaint_(F).pdf.


1116 http://iaomt.org/news/archive.asp?intReleaseID=323 accesssed 5 April 2010.


1117 International Programme on Chemical Safety (IPCS) (2003) Concise International Chemical

Assessment Document 50.

http://www.who.int/ipcs/publications/cicad/en/cicad50.pdf accessed 06 June 2008.


1118 http://www.geocities.com/Athens/9313/dent.html accessed 23 May 2009.


1119 Dr. David E. Barnes, Plaintiff-appellant/cross-appellee, v. the Kerr Corporation, Defendant-

appellee/cross-appellant United States Court of Appeals, Sixth Circuit. - 418 F.3d 583

Argued: July 20, 2005 Decided and Filed: August 11, 2005.

http://cases.justia.com/us-court-of-appeals/F3/418/583/544495/ accessed 9 August 2009.


1120 http://mercurypolicy.org.


1121 http://mpp.cclearn.org/wp-content/uploads/2008/08/attached-letter-from-the-subcommittee-to-epa-administrator-steve-johnson.pdf.


1122 Guidelines for the Use of Dental Restorative Materials. Information to dental health personnel about

the use of dental materialsfor restoring single teeth. Issued by the Norwegian Directorate for Health

and Social Welfare, Norway issued 12/2003.

http://www.helsedirektoratet.no/vp/template/ver1-0/print.jsp?articleId=5695&sectionId=268 and

http://www.helsedirektoratet.no/vp/multimedia/archive/00001/A_National_Clinical_G_1661a.pdf

accessed 9 March 2009. Order reference: IS-1136.


1123 http://www.kemi.se/templates/Page.aspx?id=5233


1124 Spencer AJ, et al. Dental amalgam and mercury in dentistry. Aust Dent J, 2000 Dec:45(4):224-34.


1125 Spencer AJ, et al. Dental amalgam and mercury in dentistry. Aust Dent J, 2000 Dec:45(4):224-34.


1126 http://www.iaomt.org/news/files/files295/Amalgaminformationsheet_PDPH_2-6-09.pdf.


1127 http://www.ada.org/public/media/releases/0207_release01.asp accessed on 06 June 2008 and

still proclaiming that the FDA sees amalgams as safe.


1128 http://www.dental-tribune.com/articles/content/id/1146.
 

For the whole family

Cape Town Smile Studio

You are here: Home The Big Dental Lie References 501 - 1128

Strong White Teeth

Strong white Teeth

Keep Smiling!

Keep Smiling!

Professionals who Care!

Professionals who Care!